triamcinolone profile

Triamcinolone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. Its synthesis involves multiple steps starting from prednisone and utilizing various chemical reactions. Triamcinolone is widely used in the treatment of inflammatory conditions such as rheumatoid arthritis, asthma, and skin disorders. It works by suppressing the immune system, reducing inflammation, and inhibiting the release of inflammatory mediators. The drug has a high affinity for glucocorticoid receptors, leading to its potent effects. Extensive research on triamcinolone focuses on understanding its mechanisms of action, optimizing its therapeutic uses, and exploring its potential for new applications. Its effectiveness in managing inflammatory conditions makes it an important drug in medicine.'

Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	31307
CHEMBL ID	1451
CHEBI ID	9667
SCHEMBL ID	4447
MeSH ID	M0021894

Synonym
MLS001066543 ,
AC-2072
MLS002695935
BRD-K77554836-001-03-3
gtpl2870
MLS000028542 ,
EU-0101179
BPBIO1_000154
rodinolone
pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-
9.alpha.-fluoro-16.alpha.-hydroxyprednisolone
volon
triamcinolone
triam-tablinen
nsc13397
aristocort
nsc-13397
11.beta.,17.alpha.,21-tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
9.alpha.-fluoro-11.beta.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
triamcinlon
prednisolone, 9-fluoro-16.alpha.-hydroxy-
tricortale
triamcinolon
fluoxyprednisolone
cl 19823
delphicort
9.alpha.-fluoro-11.beta.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
sk-triamcinolone
pregna-1,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-
124-94-7
ledercort
9.alpha.-fluoro-11.beta.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
triamcet
celeste
cinolone-t
wln: l e5 b666 ov ku mutj a1 bf cq e1 fv1q fq gq
adcortyl
kenacort
PRESTWICK_438
cas-124-94-7
PRESTWICK2_000120
LOPAC0_001179
BSPBIO_000140
9.alpha.-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
pregna-1,4-diene-3, 20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-
(8s,9r,10s,11s,13s,14s,16r,17s)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
9.alpha.-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9-fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
11.beta.,16.alpha.,17.alpha., 21-tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
9.alpha.-fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-dione
SMP1_000300
9-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
einecs 204-718-7
aristocort tablets
triamcinolona [inn-spanish]
mycolog
tiamcinolonum [inn-latin]
prednisolone, 9-fluoro-16alpha-hydroxy-
nsc 13397
pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11-beta,16-alpha)-
11-beta,16-alpha,17-alpha,21-tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
brn 2341955
hsdb 3194
9-alpha-fluoro-16-alpha-hydroxyprednisolone
omcilon
pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-
pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-
kenacort-ag
triamcinolonum [inn]
triamcinalone
11beta,16alpha,17alpha,21-tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
9alpha-fluoro-16alpha-hydroxyprednisolone
9alpha-fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
DB00620
triamcinolone (jp17/usp/inn)
D00385
kenacort (tn)
NCGC00021580-05
smr000058333
NCI60_000750
SPBIO_002079
PRESTWICK0_000120
PRESTWICK1_000120
PRESTWICK3_000120
NCGC00021580-04
NCGC00021580-03
NCGC00021580-06
HMS2090D12
NCGC00021580-07
chebi:9667 ,
fluoxiprednisolone
CHEMBL1451
HMS1568G22
NCGC00021580-08
HMS3263L19
HMS2095G22
51855-44-8
pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-, tetrahydro deriv.
tox21_300178
NCGC00254049-01
dtxcid9020742
tox21_111332
dtxsid1040742 ,
pregna-1,4-diene-3,20-dione,9-fluoro-11,16,17,21-tetrahydroxy-, (11b,16a)-
CCG-205253
HMS2231E20
(8s,9r,10s,11s,13s,14s,16r,17s)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
triamcinolona
triamcinolone [usp:inn:ban:jan]
4-08-00-03629 (beilstein handbook reference)
unii-1zk20vi6ty
triamcinolonum
tiamcinolonum
1zk20vi6ty ,
triamcinolone, topical
LP01179
(11beta,16alpha)-9-fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
S1933
AKOS015895436
triamcinolone [ep monograph]
triamcinolone [mi]
triamcinolone [hsdb]
triamcinolone [vandf]
triamcinolone acetonide impurity a [ep impurity]
triamcinolone [usp-rs]
pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)
triamcinolone [who-dd]
triamcinolone [jan]
9-fluoro-11,beta,,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
triamcinolone [orange book]
triamcinolone [inn]
triamcinolone [mart.]
triamcinolone [green book]
triamcinolone [usp monograph]
HY-B0328
SCHEMBL4447
NCGC00178404-03
tox21_111332_1
GFNANZIMVAIWHM-OBYCQNJPSA-N
tox21_501179
NCGC00261864-01
cid_31307
bdbm41132
triamcinolone, british pharmacopoeia (bp) reference standard
(1r,2s,10s,11s,13r,14s,15s,17s)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
sr-01000000079
SR-01000000079-3
triamcinolone, united states pharmacopeia (usp) reference standard
triamcinolone, european pharmacopoeia (ep) reference standard
triamcinolone acetonide imp. a (ep); triamcinolone; triamcinolone acetonide impurity a
HMS3712G22
124-94-7 (free)
3-[2[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-piperidine
E70344
EX-A4109
AS-13657
BCP11941
brn-2341955
Q1074056
BRD-K77554836-001-14-0
SDCCGSBI-0051146.P002
NCGC00021580-16
triamcinolone (standard)
CS-0695010
HY-B0328R
(1s,2r,3as,3bs,9as,9br,10s,11as)-9b-fluoro-1,2,10-trihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
EN300-7400440
triamcinolone (mart.)
tiamcinolonum (inn-latin)
triamcinolona (inn-spanish)
triamcinolone (usp monograph)
triamcinolone (usp:inn:ban:jan)
triamcinolone (usp-rs)
triamcinolone (ep monograph)

Excerpt	Reference	Relevance
"Triamcinolone (TA) is a hormone corticosteroid drug used to treat edema, inflammation, and angiogenic eye diseases. "	( Diabetic Retinopathy Analysis-Effects of Nanoparticle-Based Triamcinolone. Du, S; Jiang, F; Wang, H; Wang, Y, 2020)	2.24
"Triamcinolone is a long acting corticosteroid used in the treatment of arthritis, eczema, psoriasis and similar conditions which cause inflammation. "	( Optimization of Microemulsion Based Transdermal Gel of Triamcinolone. Chaudhari, B; Jagdale, S, 2017)	2.15
"Triamcinolone (T) is a glucocorticoid commonly used to relieve inflammation and treat arthritis, severe allergies, and asthma; however, it is banned by the World Anti-Doping Agency in competition for athletes when administered orally, intravenously, intramuscularly, or rectally. "	( Elimination profile of triamcinolone in urine following oral administration. Chang-Chien, GP; Chen, TT; Hsu, MC; Huang, TY; Tseng, YC, 2018)	2.23
"Triamcinolone is a long-acting glucocorticoid medication that can be responsible for transient suppression of the hypothalamic–pituitary–adrenal (HPA) axis. "	( Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. Bush, LM; Schroeder, JR; Song, Y, )	1.8
"Triamcinolone is a long-acting glucocorticoid medication that can be responsible for transient suppression of the hypothalamic–pituitary–adrenal (HPA) axis. "	( Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. Bush, LM; Schroeder, JR; Song, Y, )	1.8
"Triamcinolone is an anti-inflammatory drug currently used in Ophthalmology for the treatment of various conditions. "	( Severe complication during strabismus surgery. García de Oteyza, G; García de Oteyza, J, 2016)	1.88
"Triamcinolone is a highly effective and safe short-term treatment for persistent physiological or pathological phimosis. "	( Topical triamcinolone for persistent phimosis. Abdo, A; Barrieras, D; Franc-Guimond, J; Houle, AM; Letendre, J, 2009)	2.23
"Triamcinolone acetonide is a steroidal antiinflammatory agent."	( Inhibition of ultraviolet-B epidermal ornithine decarboxylase induction and skin carcinogenesis in hairless mice by topical indomethacin and triamcinolone acetonide. Breeding, J; Chalet, M; Connor, MJ; Lowe, NJ, 1982)	1.19
"Triamcinolone is a commonly used synthetic corticosteroid that has recently been tested in a large clinical trial for chronic obstructive pulmonary disease and shown to have some benefits. "	( Triamcinolone: new and old indications. Doggrell, SA, 2001)	3.2

Excerpt	Reference	Relevance
"Triamcinolone has been widely used due to its efficacy in bringing about pain reduction for up to three months."	( "Platelet-Rich Plasma" epidural injection an emerging strategy in lumbar disc herniation: a Randomized Controlled Trial. Chanplakorn, P; Jitpakdee, K; Kotheeranurak, V; Laohapornsvan, P; Pairuchvej, S; Wongjarupong, A; Yeekian, C, 2023)	1.63
"Triamcinolone has half-life of 88min."	( Optimization of Microemulsion Based Transdermal Gel of Triamcinolone. Chaudhari, B; Jagdale, S, 2017)	1.42
"Triamcinolone has antifibroblast and anticollagen properties."	( Internal urethrotomy and intraurethral submucosal injection of triamcinolone in short bulbar urethral strictures. Alizadeh, F; Ghalamkari, A; Izadpanahi, MH; Kabiri, M; Khorrami, MH; Mazdak, H; Mohammadi, A; Nouri-Mahdavi, K; Tadayyon, F; Yazdani, M; Zargham, M, 2010)	1.32
"Triamcinolone acetonide has been shown to decrease both cellular proliferation and collagen production by dermal fibroblasts. "	( Triamcinolone stimulates bFGF production and inhibits TGF-beta1 production by human dermal fibroblasts. Carroll, LA; Hanasono, MM; Kita, M; Koch, RJ; Mikulec, AA, 2002)	3.2
"Triamcinolone has anti-inflammatory properties and the anti-inflammatory effects of montelukast and formoterol have been discussed."	( A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Jerzynska, J; Kuna, P; Stelmach, I, 2002)	1.04

Excerpt	Reference	Relevance
"Triamcinolone does not increase pain relief or lengthen the effects of EUS-CPB."	( Adding triamcinolone to endoscopic ultrasound-guided celiac plexus blockade does not reduce pain in patients with chronic pancreatitis. Costanzo, A; Kapural, L; Lopez, R; Parsi, MA; Stevens, T; Vargo, JJ, 2012)	2.28
"Triamcinolone may inhibit some cellular responses that accompany hypoxia."	( Triamcinolone does not alter glial cell activation in the experimentally detached rabbit retina. Bringmann, A; Pannicke, T; Reichenbach, A; Uckermann, O; Uhlmann, S; Wiedemann, P, 2005)	2.49
"Triamcinolone failed to activate the glands of oophorectomized animals."	( Triamcinolone-induced mammary activation in virgin mice. Lindenbaum, E; Silberman, M, 1978)	2.42

Excerpt	Reference	Relevance
"Triamcinolone treatment of BPS patients."	( Urine Gene Expression Profiles in Bladder Pain Syndrome Patients Treated with Triamcinolone. Alcaraz, A; Franco, A; Gómez, A; Ingelmo-Torres, M; Izquierdo, L; Lozano, JJ; Mateu, L; Mengual, L; Montalbo, R; Peri, L, 2020)	2.23
"Triamcinolone-treated CCI rats had a statistically significant reduction in the magnitude of heat-hyperalgesia and mechano-allodynia, but there was no effect on cold-allodynia or mechano-hyperalgesia."	( Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy. Bennett, GJ; Hayashi, R; Kawamoto, M; Xiao, W; Yuge, O, 2008)	1.07
"Triamcinolone treatment also resulted in small rises in serum glucagon but these changes did not appear to be of importance for the observed bimodal serum lipoprotein perturbations."	( Origin and pattern of glucocorticoid-induced hyperlipidemia in rats. Dose-dependent bimodal changes in serum lipids and lipoproteins in relation to hepatic lipogenesis and tissue lipoprotein lipase activity. Bar-On, H; Krausz, Y; Shafrir, E, 1981)	0.98
"Triamcinolone pretreatment enhances the 2N facilitatory actions of amitriptyline (AMIT), 5 mg/kg i.v., when given after D,L-5-hydroxytryptophan (5--HTP), 50 mg/kg i.v., as compared to untreated control preparations."	( Glucocorticoid effects on serotonergic and noradrenergic facilitation of spinal monosynaptic transmission. Hall, ED, 1980)	0.98
"Triamcinolone pretreatment for 48 h, however, elevated the basal diglyceride levels, but the increase after the addition of PTH was totally abolished."	( Effect of triamcinolone on parathyroid hormone-stimulated second messenger systems and phosphate transport in opossum kidney cells. Baldassare, JJ; Jacob, AK; Martin, KJ; McConkey, CL, 1994)	1.41
"In triamcinolone-pretreated rats the structure of the cortex appeared to be virtually normal and tissue of medulla was only slightly damaged."	( Protective effect of antiinflammatory corticosteroid triamcinolone in cisplatin nephrotoxicity. Gambaryan, SP; Reznik, LV, )	0.89
"Triamcinolone treatment (12 mg/kg intraperitoneally, once daily for 3 days) reduced mean right ventricular pressure (11 +/- 1 versus 14 +/- 1 mm Hg) and protein content of pulmonary arteries (1.8 +/- 0.1 versus 2.7 +/- 0.1 mg/vessel) (both p < 0.05)."	( Effect of glucocorticoids on collagen accumulation in pulmonary vascular remodeling in the rat. Choe, JK; Poiani, GJ; Riley, DJ; Thakker-Varia, S; Tozzi, CA, 1994)	1.01
"Triamcinolone treatment did not affect plasma protein and albumin levels but increased the level of plasma triglycerides and cholesterol in the very low density lipoprotein (VLDL) and LDL but not high density lipoprotein fractions."	( Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine. Shafrir, E, 1996)	1.02
"11 triamcinolone-treated rats)(P<0.01), which was paralleled by an increase in serum apoA-I (76+/-21 vs."	( Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats. Akita, H; Chiba, H; Fuda, H; Hui, SP; Kobayashi, K; Nagasaka, H; Takahashi, Y, 1997)	1.2
"Triamcinolone treatment also lessened the inhibition of glucose-6-phosphatase by pyridoxal 5'-phosphate (PLP), but this effect was not due to an interaction of PLP with the active site."	( Evidence that the transit of glucose into liver microsomes is not required for functional glucose-6-phosphatase. Annabi, B; van de Werve, G, 1997)	1.02
"Triamcinolone acetonide treatment resulted in improvement from baseline of 17% for FEV1 (P < .0001); 44% for albuterol use (P = .0009); 9% for FVC (P = .0185); 19% for PEF (P = .0011); 42% for FEF25-75% (P < .0001); 8% for FEV1/FVC (P = .0016); 36% for daytime, 39% for nighttime, and 38% for total asthma symptoms (P < or = .0001); and 12% for morning, and 10% for evening PEF (P < or = .001). "	( A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma. Banerji, D; Fish, L; Graft, D; Higgins, N; Kavuru, M; Pleskow, W; Ramsdell, JW, 1998)	2.02
"2. Triamcinolone treatment reduced the normalised overall amount of all SERCA mRNA in diaphragm by 70 % compared to controls (P < 0.05)."	( Corticosteroids decrease mRNA levels of SERCA pumps, whereas they increase sarcolipin mRNA in the rat diaphragm. Decramer, M; Gayan-Ramirez, G; Vanzeir, L; Wuytack, F, 2000)	0.82
"Triamcinolone treatment restored both activities to normal by 24 h."	( Glucocorticoid regulation of hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression. Cayre, Y; Colosia, AD; el-Maghrabi, MR; Lange, AJ; Marker, AJ; Pilkis, SJ; Solomon, DH; Tauler, A, 1989)	1
"Triamcinolone treatment resulted in no change in muscle fiber proportions."	( Pathologic changes and contractile properties of the diaphragm in corticosteroid myopathy in hamsters: comparison to peripheral muscle. Bockhold, K; Bressler, B; Hards, JM; Pardy, RL; Wilcox, PG, 1989)	1
"Treatment with triamcinolone (1 or 50 mg/kg/day) caused phosphaturia in rats fed a low-phosphate diet and also restored rhe phosphaturic effects of PTH."	( Restoration of phosphaturic response to parathyroid hormone by glucocorticoid treatment in phosphorus-deprived rats. Berndt, JT; Czekalski, S; Dousa, TP; Holets, R; Knox, FG; Onsgard, M, 1982)	0.6
"Pretreatment with triamcinolone resulted in much less severe changes in renal function after cisplatin administration (serum urea: triamcinolone plus cisplatin 14.29 +/- 1.90 mg/l, cisplatin alone 21.60 +/- 2.34 mg/l, p < 0.05, control 2.78 +/- 0.19 mg/l, serum creatinine: triamcinolone plus cisplatin 0.21 +/- 0.02 mg/l, cisplatin alone 0.30 +/- 0.02 mg/l, p < 0.05, control 0.06 +/- 0.01 mg/l)."	( Protective effect of antiinflammatory corticosteroid triamcinolone in cisplatin nephrotoxicity. Gambaryan, SP; Reznik, LV, )	0.7
"Treatment with triamcinolone diacetate also reduced the level of several free amino acids and enhanced the activity of a myofibrillar protease in skeletal muscle."	( Interaction of glucocorticoid hormones with rat skeletal muscle: catabolic effects and hormone binding. Kaiser, N; Mayer, M; Milholland, RJ; Rosen, F; Shafrir, E, 1976)	0.6
"Pretreatment with triamcinolone and administration of exogenous alanine both attenuated the hypoglycemia and ketosis, It is concluded that 1) in states of heightened gluconeogenesis, alanine release from muscle may not keep pace with extraction by liver and blood alanine decreases; 2) the release of alanine, lactate, and pyruvate from muscle parallel each other suggesting common control factors; and 3) in the red state muscle is an important site of lactate disposition."	( Alanine metabolism and gluconeogenesis in the rat. Berger, M; MacDonald, M; Neufeldt, N; Park, BN; Ruderman, N, 1976)	0.58
"Treatment with triamcinolone is effective both in immature and in 55-day-old rats."	( Stimulation of renal tubular transport of p-aminohippurate in rats of different ages by treatment with adrenocortical steroids. Bräunlich, H; Rassbach, H; Vogelsang, S, 1992)	0.62

Excerpt	Reference	Relevance
"Comparative experiments were performed on female rats given pregnenolone-16 alpha-carbonitrile (PCN), spironolactone, triamcinolone, estradiol or diethylstilbestrol to study correlations between the toxic effect of cocaine, its blood clearance and its urinary excretion."	( Effect of steroids and diethylstilbestrol on cocaine toxicity, plasma concentrations and urinary excretion. Kourounakis, P; Rapp, U; Selye, H, 1979)	0.47
"A less frequently reported adverse side effect of local steroid injections has been described."	( Perilymphatic atrophy of skin. An adverse side effect of intralesional steroid injections. Kravette, MA, 1986)	0.27
" Thus, toxic effects can be caused by preservatives or inadequate osmolarity of the vehicles alone."	( Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Arena, JE; Chandler, D; Hida, T; Machemer, R, 1986)	0.27
"To appraise the data on systemic adverse effects of inhaled corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
"All inhaled corticosteroids exhibit dose-related systemic adverse effects, although these are less than with a comparable dose of oral corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
" The healthy volunteers tolerated the phytotherapeutic paste well, and no adverse effects could be attributed to its use."	( Safety and efficacy of Eupatorium laevigatum paste as therapy for buccal aphthae: randomized, double-blind comparison with triamcinolone 0.1% orabase. Paulo Filho, W; Pinto, DS; Ribeiro, JE, )	0.34
" These cutaneous adverse effects were dose-dependent and increased with age."	( Cutaneous adverse effects of inhaled steroids. , 2007)	0.34
" Therapy is safe and infants are at minimal risk for systemic side-effects when low doses of corticosteroid are used."	( Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. Couto, JA; Greene, AK, 2014)	0.64
" EE-DCR with adjunctive MMC and TA is a safe and successful procedure for the treatment of NLDO."	( Safety and efficacy of adjunctive intranasal mitomycin C and triamcinolone in endonasal endoscopic dacryocystorhinostomy. Cheng, AC; Li, EY; Sze, AM; Wong, AC; Yuen, HK, 2016)	0.68
"Intrapolyp steroid injection appears to be an effective and safe method for treatment of nasal polyps, with comparable results to oral short-term steroid treatment."	( Intrapolyp steroid injection for nasal polyposis: Randomized trial of safety and efficacy. Bercin, S; Gul, F; Kırıs, M; Muderris, T; Sevil, E; Yalçıner, G, 2016)	0.43
" Data on the mean change of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were extracted, and adverse events (AEs) were collected."	( The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis. Gao, Y; Lan, J; Wang, W; Xie, L; Zhang, L, 2016)	0.43
"Sub-tenon triamcinolone injection was found to be a safe and effective alternative to topical dexamethasone for control of post-operative inflammation after phacoemulsification."	( Comparison of the safety and efficacy of single injection of subtenon triamcinolone and topical dexamethasone in reducing postoperative inflammation after phacoemulsification and intraocular lens implantation. Alam, M; Khan, A; Khan, H, 2016)	1.07
" Most adverse effects were transient, but 13 hands exhibited persistent skin depigmentation or subcutaneous atrophy."	( Safety of corticosteroid injection for carpal tunnel syndrome. Bland, JDP; Kaile, E, 2018)	0.48
" Data collected included patient characteristics, results of cytologic and histologic testing and tumor staging, triamcinolone dosage, treatment response, and adverse events."	( Safety and efficacy of intralesional triamcinolone administration for treatment of mast cell tumors in dogs: 23 cases (2005-2011). Burgess, K; Case, A, 2018)	0.96
" Although the treatment is generally safe and effective, adverse side effects such as swelling and edema postinjection are common and can sometimes be debilitating."	( Randomized, Double-Blinded, Sham-Controlled, Split-Hand Trial Evaluating the Safety and Efficacy of Triamcinolone Acetate Injection After Calcium Hydroxylapatite Volume Restoration of the Dorsal Hand. Goldman, MP; Wu, DC, 2018)	0.7
"In this study, the authors explore the utility of triamcinolone acetate coinjection with CaHA to the dorsal hands to mitigate adverse effects and improve patient experience."	( Randomized, Double-Blinded, Sham-Controlled, Split-Hand Trial Evaluating the Safety and Efficacy of Triamcinolone Acetate Injection After Calcium Hydroxylapatite Volume Restoration of the Dorsal Hand. Goldman, MP; Wu, DC, 2018)	0.95
"The addition of triamcinolone acetate coinjection with CaHA for dorsal hand augmentation did not negatively impact treatment efficacy but significantly reduced adverse side effects."	( Randomized, Double-Blinded, Sham-Controlled, Split-Hand Trial Evaluating the Safety and Efficacy of Triamcinolone Acetate Injection After Calcium Hydroxylapatite Volume Restoration of the Dorsal Hand. Goldman, MP; Wu, DC, 2018)	1.04
" No adverse events were observed peri- and postoperatively."	( Intracochlear administration of steroids with a catheter during human cochlear implantation: a safety and feasibility study. Gaertner, L; Lenarz, T; Prenzler, NK; Salcher, R; Timm, M; Warnecke, A, 2018)	0.48
" The target Nail Psoriasis Severity Index (NAPSI) score of each finger was evaluated, any adverse effects were recorded, and photographs were taken."	( A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails. Boontaveeyuwat, E; Danchaivijitr, N; Silpa-Archa, N; Wongpraparut, C, 2019)	0.75
"In spite of its temporary effect, the intralesional triamcinolone injection is an effective and safe treatment for psoriatic nails."	( A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails. Boontaveeyuwat, E; Danchaivijitr, N; Silpa-Archa, N; Wongpraparut, C, 2019)	1
"Intralesional steroid injection plus oral steroid administration is safe and effective in preventing stricture following esophageal ESD for esophageal epithelial neoplasms with a mucosal defect extending no less than two-thirds of the circumference in a long-term follow-up."	( Long-term efficacy and safety of intralesional steroid injection plus oral steroid administration in preventing stricture after endoscopic submucosal dissection for esophageal epithelial neoplasms. Chen, T; Chen, W; Chu, Y; Li, H; Xu, M; Yao, L; Zhang, Y; Zhong, Y; Zhou, P, 2019)	0.51
" However, normalization of HPA axis function by day 7 suggests that although acute steroid side effects should be discussed with patients, no cumulative systemic steroid side effect would occur with serial injections."	( Systemic safety of serial intralesional steroid injection for subglottic stenosis. Paddle, P; Phyland, D; Woliansky, J, 2019)	0.51
" Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous haemorrhage (VH) and retinal tear."	( Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion. Li, M; Qian, T; Wan, Y; Xu, X; Zhao, M, 2018)	0.48
"The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions."	( Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019)	0.99
" However, an unintended but frequent consequence of ICI therapy is the development of cutaneous immune-related adverse events (irAEs), such as lichenoid dermatitis irAEs (LD-irAEs)."	( Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II, 2020)	0.56
"In-office compounding for intralesional dermal and subcutaneous administration is safe when sterile products are used by medical practitioners."	( The infection rate of intralesional triamcinolone and the safety of compounding in dermatology for intradermal and subcutaneous injection: A retrospective medical record review. Al Shabeeb, R; Eleryan, M; Griffith, JL; Kurland, E; Luther, CA; Ozog, DM; Redbord, K, 2020)	0.83
" All patients were evaluated by dermoscope before treatment and at each follow-up visit to record any adverse effects of treatment."	( Efficacy and safety of intralesional steroid injection in the treatment of melasma. Ibrahim, AM; Mahmoud, AA; Nassar, AAE, 2021)	0.62
" The presence of antidrug antibodies was not associated with adverse events or altered pain reduction."	( A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Åkerblad, AC; Keenan, RT; Khanna, PP; Ohlman, S; Osterling Koskinen, L; Pillinger, MH; Saag, KG; So, A; Sparve, E; Terkeltaub, R; Wikén, M, 2021)	0.62
" Corticosteroid administration within this space is hypothesized to be safe and effective at controlling intraocular inflammation, especially in horses with poorly responsive ERU."	( Efficacy and safety of suprachoroidal triamcinolone injection in horses with poorly responsive equine recurrent uveitis. Gagnon, NA; Gilger, BC; Hartley, C, 2021)	0.89
" Adverse effects after injections occurred in <20% of the horses at follow-up, but some of these effects were attributed to chronic inflammation prior to effective treatment, long-term topical corticosteroid use, or complications from hospitalization rather than the SCS injections."	( Efficacy and safety of suprachoroidal triamcinolone injection in horses with poorly responsive equine recurrent uveitis. Gagnon, NA; Gilger, BC; Hartley, C, 2021)	0.89
"Based on these results, SCS TA injections appear to be a safe and possible effective treatment modality for managing poorly responsive ERU; further clinical study is warranted."	( Efficacy and safety of suprachoroidal triamcinolone injection in horses with poorly responsive equine recurrent uveitis. Gagnon, NA; Gilger, BC; Hartley, C, 2021)	0.89
" Accurate collection and analysis of best-corrected visual acuity (BCVA), central foveal thickness (CFT), intraocular pressure (IOP), and adverse events (AEs) were carried out in order to evaluate visual function and macular morphology before and after treatment."	( Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal). Bonifazzi, C; Parmeggiani, F; Sorrentino, FS, 2021)	0.85
"Intravitreal injection of preservative-free triamcinolone (Taioftal) is an effective, safe and inexpensive drug used to improve visual acuity and reduce central foveal thickness in eyes affected by diabetic macular edema during an average time of 6 months."	( Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal). Bonifazzi, C; Parmeggiani, F; Sorrentino, FS, 2021)	1.12
" Overall, corticosteroids reduced inflammatory complications after 3MS and did not show any serious adverse effects."	( Comparative efficacy and safety of different corticosteroids to reduce inflammatory complications after mandibular third molar surgery: a systematic review and network meta-analysis. Canellas, JVDS; Ritto, FG; Tiwana, P, 2022)	0.72
"Dropless cataract regime was found to be an effective and safe alternative that was easy to administer."	( Efficacy and safety of intravitreal injection of triamcinolone-moxifloxacin after cataract surgery in a low to middle income country - a one-year audit. Jeeva, IK; Masud, S; Siddiqui, MAR, 2023)	1.16

Excerpt	Reference	Relevance
"Plasma levels of triamcinolone were measured by RIA (radioimmunoassay) on 10 patients following oral application of 16 mg triamcinolone (Delphicort), the pharmacokinetic parameters were calculated."	( [Pharmacokinetics of triamcinolone following oral administration]. Barth, J; Möllmann, H; Pörtner, M; Rohdewald, P, 1988)	0.93
" Plasma levels of diclofenac were measured and pharmacokinetic parameters were calculated."	( Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Barth, J; Derendorf, H; Grüner, A; Möllmann, H; Mullersman, G, 1986)	0.49
" Twenty-two different pharmacodynamic parameters were followed as a function of time for 48 hours."	( Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. Barth, J; Derendorf, H; Hochhaus, G; Krieg, M; Möllmann, C; Möllmann, H; Tunn, S, 1993)	0.29
" The method was validated before using to pharmacokinetic studies."	( RP-HPLC method with fluorescence detection for determination of small quantities of triamcinolone in plasma in presence of endogenous steroids after derivatization with 9-anthroyl nitrile; pharmacokinetic studies. Główka, FK; Karaźniewicz, M; Lipnicka, E, 2006)	0.56
" The validated method was successfully applied to determine the plasma concentrations of triamcinolone acetonide in healthy volunteers, in a pharmacokinetic study with nasal spray formulation."	( Determination of triamcinolone in human plasma by a sensitive HPLC-ESI-MS/MS method: application for a pharmacokinetic study using nasal spray formulation. Bellorio, KB; Brêtas, JM; Byrro, RM; César, IC; de Santana e Silva Cardoso, FF; de Sousa, WC; de Souza Teixeira, L; Gomes, SA; Mundim, IM; Pianetti, GA, 2011)	0.93

Excerpt	Reference	Relevance
"An experimental dog model was used to reproduce the clinical picture of bilateral arteriole and choriocapillaris occlusion from a unilateral intracarotid injection of long-acting corticosteroids combined with other drugs including lidocaine, epinephrine, and penicillin."	( Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: II. Animal experimental studies. McGrew, RN; White, HJ; Wilson, RS, 1978)	0.26
" The use of morphine alone or combined with slow release triamcinolone does not appear to be appropriate for the treatment of the post-laminectomy pain syndrome."	( Epidural steroids, epidural morphine and epidural steroids combined with morphine in the treatment of post-laminectomy syndrome. Frank, E; Gallo, JP; Kaul, AF; Lipson, SJ; Rocco, AG, 1989)	0.52
"Seventy-five mg diclofenac sodium were given intramuscularly to 15 subjects alone and in combination with 40 mg triamcinolone acetate."	( Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Barth, J; Derendorf, H; Grüner, A; Möllmann, H; Mullersman, G, 1986)	0.7
" In the presence of serum, GM-CSF or TNF-alpha could increase LC frequency compared to the control; but in the absence of serum neither of these cytokines were effective unless they were combined with each other."	( Modulation of MHC class II+ Langerhans cell numbers in corticosteroid treated epidermis by GM-CSF in combination with TNF-alpha. Halliday, GM; O'Sullivan, GM, 1997)	0.3
"Initial pulse triple therapy consisting of single-session PDT combined with IVB and IVT improves vision and reduces CMT in neovascular AMD."	( Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. Ahmadieh, H; Azarmina, M; Dehghan, MH; Karkhaneh, R; Lashay, A; Moradian, S; Riazi-Esfahani, M; Soheilian, M; Taei, R, 2007)	0.57
" While earlier trials have either compared corticosteroid injections to physical therapy or to naproxen orally, we will compare the clinical effect of physiotherapy alone or physiotherapy combined with corticosteroid injection in the initial treatment of acute tennis elbow."	( Physiotherapy alone or in combination with corticosteroid injection for acute lateral epicondylitis in general practice: a protocol for a randomised, placebo-controlled study. Brage, S; Holmedal, Ø; Lindbaek, M; Olaussen, M, 2009)	0.35
"To evaluate the 12-month clinical outcome of patients with persistent non-ischaemic diffuse diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB) or with intravitreal injection of triamcinolone combined with macular laser grid (IVTA-MLG) from September 2005 to February 2008."	( Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Cennamo, G; Cennamo, GL; D'Amico, G; de Crecchio, G; Farese, E; Finelli, M; Forte, R; Nicoletti, G, 2010)	0.81
" The patient underwent 10 treatment sessions with the 595-nm long-pulsed dye laser followed immediately by the 1450-nm diode laser in combination with intralesional triamcinolone and 5-fluorouracil."	( 595-nm long pulsed dye laser and 1450-nm diode laser in combination with intralesional triamcinolone/5-fluorouracil for hypertrophic scarring following a phenol peel. Friedman, PM; Glaich, AS; Goldberg, LH; Katz, TM, 2010)	0.78
" This report illustrates the potential safety and efficacy of serial intralesional steroids combined with balloon dilation as an alternative to more invasive treatments."	( Serial intralesional steroid injection combined with balloon dilation as an alternative to open repair of subglottic stenosis. Bent, J; Edmondson, NE, 2010)	0.36
"To present long-term data on the progression of cataracts following photodynamic therapy (PDT) combined with 4 mg intravitreal triamcinolone acetonide (IVTA) for age-related macular degeneration (AMD)."	( Progression of cataracts following photodynamic therapy combined with intravitreous triamcinolone injection in cases of age-related macular degeneration. Ataka, S; Iwami, H; Kaida, M; Kohno, T; Miki, N; Shiraki, K; Yamamoto, M, 2011)	0.8
"This study showed high incidence of cataract during a long-term follow-up after PDT combined with IVTA and significant reduction of visual acuity due to cataract."	( Progression of cataracts following photodynamic therapy combined with intravitreous triamcinolone injection in cases of age-related macular degeneration. Ataka, S; Iwami, H; Kaida, M; Kohno, T; Miki, N; Shiraki, K; Yamamoto, M, 2011)	0.59
"To compare the use of intralesional triamcinolone acetonide and its combination with 5 flourouracil in the treatment of keloid and hypertrophic scars in terms of reduction in initial height of the scar."	( Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Bashir, MM; Khan, FA; Khan, MA, 2014)	1.04
"We included randomised controlled trials (RCTs) of intravitreal anti-VEGF combined with intravitreal steroids versus intravitreal anti-VEGF alone, intravitreal steroids alone or macular laser alone for managing DMO."	( Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Campain, A; Fraser-Bell, S; Gillies, MC; Hennings, C; Mehta, H; Nguyen, V, 2018)	0.48
" The anti-VEGF agent was combined with intravitreal triamcinolone in six studies and with an intravitreal dexamethasone implant in two studies."	( Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Campain, A; Fraser-Bell, S; Gillies, MC; Hennings, C; Mehta, H; Nguyen, V, 2018)	0.73
"We present the case of a 58-year-old HIV-infected patient with adrenal insufficiency after local injection of triamcinolone, most likely due to drug-drug interaction with his ritonavir-boosted antiretroviral therapy (ART)."	( Adrenal insufficiency due to ritonavir-triamcinolone drug-drug interaction without preceding Cushing's syndrome. Heldwein, S; Jaeger, H; Noe, S, 2018)	0.96
"to study the efficacy and safety of the use of subconjunctival triamcinolone acetate alone or in combination with mitomycin C as a modulator of trabeculectomy healing in rabbits."	( Healing modulation in glaucoma surgery after application of subconjunctival triamcinolone acetate alone or combined with mitomycin C: an experimetal study. Araújo, ID; Cronemberger, S; Rangel, HMDA; Rolim, HT; Vidigal, P, 2018)	0.95
"We report a diagnosis of exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction (DDI) between intrabursal triamcinolone and the pharmacokinetic booster cobicistat."	( Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone. Macpherson, G; Makaram, N; Roberts, SB; Russell, CD; Stevens, J, 2018)	0.88
" The aim of this study is to investigate the safety concerns regarding intralesional injection of lauromacrogol combined with triamcinolone for IH and to study its effect on infant growth and development."	( Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019)	0.96
"Recently, pulsed dye laser (PDL) combined with triamcinolone intralesional injection (TAILI) has been introduced for surgical scar prevention."	( Evaluating outcomes of pulsed dye laser therapy combined with intralesional triamcinolone injection after surgical removal of hypertrophic cesarean section scars. Hong, JS; Huh, CH; Kim, JW; Na, JI; Shin, JW; Yoon Park, J, 2022)	1.21
"This study aimed to evaluate the outcome of early intervention using PDL combined with TAILI after surgical removal of hypertrophic cesarean section (CS) scars."	( Evaluating outcomes of pulsed dye laser therapy combined with intralesional triamcinolone injection after surgical removal of hypertrophic cesarean section scars. Hong, JS; Huh, CH; Kim, JW; Na, JI; Shin, JW; Yoon Park, J, 2022)	0.95
"Early intervention using PDL combined with TAILI could prevent the recurrence or progression of hypertrophic CS scarring after surgical scar removal."	( Evaluating outcomes of pulsed dye laser therapy combined with intralesional triamcinolone injection after surgical removal of hypertrophic cesarean section scars. Hong, JS; Huh, CH; Kim, JW; Na, JI; Shin, JW; Yoon Park, J, 2022)	0.95
" This review assesses recurrence and the reporting of recurrence in pathologic scar after treatment with intralesional triamcinolone (TAC) in combination with another intralesional agent."	( Recurrence rates in the treatment of keloids and hypertrophic scars with intralesional triamcinolone combined with other intralesional agents. Chandy, RJ; Feldman, SR; Khan, D; Rimmer, SN, 2023)	1.34

Excerpt	Reference	Relevance
"The goal of this study was to establish a reliable method to evaluate systemic bioavailability and to determine equisystemic effects (microgram dose producing equal systemic cortisol suppression) of inhaled corticosteroids (ICS)."	( Systemic effect comparisons of six inhaled corticosteroid preparations. Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002)	0.31
" CONCLUSIONS Triamcinolone has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats disease."	( Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Bouhaimed, M; Moussa, M; Othman, IS, 2010)	0.96
" However, when this glucocorticoid agent is given to patients receiving the HIV protease inhibitor (PI) ritonavir (RTV),inhibition of their shared cytochrome P450 3A4 degradation pathway leads to an increased bioavailability of triamcinolone, with subsequent heightening and prolongation of the glucocorticoid serum levels."	( Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. Bush, LM; Schroeder, JR; Song, Y, )	0.54
" However, when this glucocorticoid agent is given to patients receiving the HIV protease inhibitor (PI) ritonavir (RTV),inhibition of their shared cytochrome P450 3A4 degradation pathway leads to an increased bioavailability of triamcinolone, with subsequent heightening and prolongation of the glucocorticoid serum levels."	( Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. Bush, LM; Schroeder, JR; Song, Y, )	0.54
" This would be a promising tool to deliver triamcinolone with enhanced bioavailability and reduced dosing frequency."	( Optimization of Microemulsion Based Transdermal Gel of Triamcinolone. Chaudhari, B; Jagdale, S, 2017)	0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The intraocular instillation method can improve the bioavailability of TA by loading the drug on to a nanostructured lipid carrier (NLC)."	( Diabetic Retinopathy Analysis-Effects of Nanoparticle-Based Triamcinolone. Du, S; Jiang, F; Wang, H; Wang, Y, 2020)	0.8
" Herein we report a new, allosteric MMP-13 inhibitor, AQU-019, that has been optimized for potency, metabolic stability, and oral bioavailability through a combination of structure activity relationship (SAR) and deuterium substitution as a potential disease modifying OA drug (DMOAD)."	( Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis. Bendele, AM; Neelagiri, M; Neelagiri, V; Sucholeiki, I, 2021)	0.62

Excerpt	Relevance	Reference
" Emphases of the description are general principles of treatment, indications and dosage in systemic and local treatment, side effects, problems of long-term treatment, application of ACTH, the cortisonoid withdrawal syndrome, prophylaxis of therapy complications and references to the reduction of the dose or to the withdrawal of the treatment with cortisonoids."	( [Cortisonoids in the therapy of rheumatic diseases]. Reinicke, C, 1977)	0.26
" Analysis of litters with deviant CP distribution, as well as of all suitable litters, indicated that only maternal treatment-day weight was significantly associated, inversely, with CP frequency-in spite of the treatment dosage having been weight-based."	( Some sources of nongenetic variability in steroid-induced cleft palate in mice. Kalter, H, 1976)	0.26
" The glucocorticoid effect on motoneuron outlasts the dosing period, suggesting an underlying alteration in the neuron."	( Glucocorticoids and mammalian motor nerve excitability. Baker, T; Okamoto, M; Riker, WF, 1975)	0.25
" A dose of 10-15 mg per day may be considered marginal for the development of cataract; dosage has no basic effect on the development of glaucoma."	( [Ophthalmic complications in general corticoid therapy]. Cepilová, Z; Krchnavá, B; Porubská, M; Slámová, J, 1991)	0.28
" A dose-response study, at the range of 2-40 mg/kg, showed that a significant decrease was noted at 6 mg/kg and it was maximal (45% inhibition) at 20 and 40 mg/kg."	( Inhibition of prostaglandin synthesis in brain of rat by dexamethasone: lack of effect of dexamethasone phosphate ester and various hormonal steroids. Abu-Amer, Y; Shohami, E; Weidenfeld, J, 1988)	0.27
" Five glucocorticoids, when administered daily to rats for 5-7 days at a dosage of 5mg/kg, were in the following order of effectiveness with respect to their ability to decrease the weight gain of whole animals and the vastus lateralis, vastus medialis and gluteus medius muscles: corticosterone	( Relative changes in the function of muscle ribosomes and mitochondria during the early phase of steroid-induced catabolism. Bullock, GR; Carter, EE; Elliott, P; Peters, RF; Simpson, P; White, AM, 1972)	0.42
" Glucocorticoid dosing significantly decreased the APO-induced depression of the spinal DRR, but not the similar action of APO on the MSR."	( Glucocorticoid modification of spinal dopamine receptor activation by apomorphine. Hall, ED; Tyler, CV, 1983)	0.27
" It is proposed that clinically the most advantageous dosage regimen is a once daily application with no loading dose."	( Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications. Barry, BW; Haigh, JM; Woodford, R, 1983)	0.27
" Systemic absorption and consequent adverse effects are rarely a problem because of low dosage administered."	( Intralesional corticosteroids. Callen, JP, 1981)	0.26
"Studies in asthma with systemic corticosteroids given at 3:00 PM have shown a superior therapeutic benefit compared with dosing at other time points."	( Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. Ackerson, LM; Martin, RJ; Pincus, DJ; Szefler, SJ, 1995)	0.29
"The study was designed to compare beneficial and systemic effects of 800 micrograms of inhaled triamcinolone once daily at 3:00 PM (QD group) versus 200 micrograms conventional four times a day dosing (QID group)."	( Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. Ackerson, LM; Martin, RJ; Pincus, DJ; Szefler, SJ, 1995)	0.51
" A dosing strategy based on once daily dosing should increase compliance of inhaled steroid use in the clinical setting."	( Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. Ackerson, LM; Martin, RJ; Pincus, DJ; Szefler, SJ, 1995)	0.29
" Experiment 1 was conducted to determine the optimum dosage of TRI and to approximate the optimum interval from TRI to induction with DEX+CLO."	( Induction of parturition in cattle: effect of triamcinolone pretreatment on the incidence of retained placenta. Barth, AD; Bo, GA; Mapletoft, RJ; Nasser, LF, 1994)	0.55
" Potency estimates were made by comparing the dose-response of natural and synthetic glucocorticoids to that of corticosterone, the major glucocorticoid in rats."	( Calcium-lowering action of glucocorticoids in adrenalectomized-parathyroidectomized rats. Specificity and relative potency of natural and synthetic glucocorticoids. Hirsch, PF; Mahgoub, A; Munson, PL, 1997)	0.3
" Thirty rats were injected either 3 or 5 times with triamcinolone in a dosage equivalent to that given to human beings or 3 or 5 times with saline into the subacromial space."	( Effect of steroid injections on the rotator cuff: an experimental study in rats. Franzén, LE; Karlsson, MH; Norlin, R; Tillander, B, )	0.38
" The selection of drugs and dosing schedules is therefore mainly guided by clinical experience."	( Management of pyoderma gangrenosum. Mokni, M; Phillips, TJ, 2001)	0.31
" The average dosage of the aforementioned solution was 6 mL (equivalent to 30 mg of triamcinolone) for the adults and 5 mL (equivalent to 25 mg of triamcinolone) for the pediatric patients."	( Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. Carlos, R; Sedano, HO, 2002)	0.54
" For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-response effect."	( Systemic effect comparisons of six inhaled corticosteroid preparations. Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002)	0.5
" Our patient demonstrated positive prick skin tests to triamcinolone in a dose-response manner, suggesting the likelihood that an immunoglobulin E-mediated hypersensitivity mechanism may play a role."	( An anaphylactic reaction to intra-articular triamcinolone: a case report and review of the literature. Karsh, J; Yang, WH, 2003)	0.83
" The questions covered frequency of intravitreal steroid injections, subspecialty interest, dosage and volume of steroid, patient preparation, surgeon preparation, and postoperative management."	( National survey of the technique of intravitreal triamcinolone injection in the United Kingdom. Anijeet, DR; Bates, RA; Bhagey, J; Hanson, RJ, 2007)	0.59
" The dosage of systemic steroids had to be augmented in two eyes."	( [Uveitic cystoid macular edema: intravitreal triamcinolone]. Feucht, M; Pressmar, S; Richard, G; Sturm, V; Weissmann, J, 2007)	0.6
"Thermal analysis has been widely used for obtaining information about drug-polymer interactions and for pre-formulation studies of pharmaceutical dosage forms."	( Thermal behavior and stability of biodegradable spray-dried microparticles containing triamcinolone. da Silva, AA; de Matos, JR; de Oliveira, AG; do Egito, ES; Formariz, TP; Rossanezi, G; Scarpa, MV, 2009)	0.58
" More studies are required to determine the optimal dosage and treatment frequency in different posterior segment disease."	( Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide. Gillies, M; Kuo, CH; McCluskey, P, 2010)	0.6
" Combination therapy can reduce the dosage of each drug but achieve equal or better efficacy than monotherapy, reducing the side effects of a single drug."	( The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. Huang, CY; Yang, JY, 2010)	0.36
" Despite the limitations of only partial maximum inhibitions, this cell-based assay could be used to quantitate the suppressing ability of glucocorticoids (transrepression potency) on the expression of proinflammatory transcription factors caused by two different cytokines in parallel both in a detailed, full dose-response format as well as in a simpler single-dose format."	( Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells. Buchwald, P; Cechin, SR, 2014)	0.4
"We included randomized controlled trials (RCTs) that compared intravitreal steroids, of any dosage and duration of treatment of at least six months, with observation for the treatment of CRVO-ME."	( Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Gewaily, D; Greenberg, PB; Muthuswamy, K, 2015)	0.42
" This would be a promising tool to deliver triamcinolone with enhanced bioavailability and reduced dosing frequency."	( Optimization of Microemulsion Based Transdermal Gel of Triamcinolone. Chaudhari, B; Jagdale, S, 2017)	0.97
" Moreover, the elimination profile of orally administered T may be crucial information for distinguishing different dosage routes."	( Elimination profile of triamcinolone in urine following oral administration. Chang-Chien, GP; Chen, TT; Hsu, MC; Huang, TY; Tseng, YC, 2018)	0.79
" oral dexamethasone versus oral prednisone), with consideration for dosing and pharmacokinetic properties, to better identify the optimal IM or oral corticosteroid regimens to improve patient outcomes."	( Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Campbell, S; Cross, E; Kirkland, SW; Rowe, BH; Villa-Roel, C, 2018)	0.48
" Median cumulative ESI dosage was 340 mg of triamcinolone or equivalent (range: 150 to 1400 mg)."	( Lower Spine Volumetric Bone Density in Patients With a History of Epidural Steroid Injections. Bockman, RS; Carrino, JA; Chukir, T; Dash, AS; Do, H; Hughes, AP; Liu, Y; Press, JM; Stein, EM, 2018)	0.74
"1% cream dosed at least twice daily for a course of 12 weeks."	( Randomized open-label trial comparing topical prescription triamcinolone to over-the-counter hydrocortisone for the treatment of phimosis. Abdelhalim, A; Chalmers, CL; Chamberlin, JD; Chuang, KW; Davis-Dao, CA; Dorgalli, C; Kelly, MS; Khoury, AE; McAleer, IM; Stephany, HA; Wang, ZT; Wehbi, EJ, 2019)	0.76
" The purpose of this study is to determine the effects of corticosteroid dosage on serum glucose levels when used to treat common hand disorders in diabetic patients."	( A Prospective Study on the Effect of Corticosteroid Injection Dosage for Hand Disorders in Non-Insulin Dependent Diabetics. Askari, M; Chen, DL; Donnally, CJ; Friend, ME; Lekic, N; Patel, AA, 2018)	0.48
" The size and number of the aggregates was determined for undiluted commercial steroid preparations in the usual amount for a single and double dosage used for ESI."	( Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation. Alvarez-Escudero, J; Cedeno, DL; Martinez, MF; Nebreda-Clavo, C; Orduna-Valls, JM; Ruiz-Sauri, A; Tornero-Tornero, C; Valverde-Navarro, AA, 2020)	0.56
" All ICSI were performed using sterile techniques, the number of ICSI in each hip and the cumulative corticosteroid dosage were assessed."	( How safe are intra-articular corticosteroid injections to the hip? Boettner, CS; Boettner, F; Braun, S; Brenneis, M; Spilo, K; Streck, LE, 2023)	0.91

Role	Description
anti-allergic agent	A drug used to treat allergic reactions.
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
fluorinated steroid	A steroid which is substituted with one or more fluorine atoms in any position.
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
21-hydroxy steroid
3-oxo-Delta(4) steroid	A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
glucocorticoid	Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
17alpha-hydroxy steroid	The alpha-stereoisomer of 17-hydroxy steroid.
16alpha-hydroxy steroid	A 16-hydroxy steroid in which the hydroxy group at position 16 has alpha-configuration.
C21-steroid hormone	A steroid compound with a structure based on a 21-carbon (pregnane) skeleton that acts as a hormone.
primary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
glp-1 receptor, partial	Homo sapiens (human)	Potency	1.0000	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	29.7607	0.1000	20.8793	79.4328	AID488773; AID588453
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	0.2298	0.0060	38.0041	19,952.5996	AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	6.9167	0.1737	34.3047	61.8120	AID1346924
ATAD5 protein, partial	Homo sapiens (human)	Potency	20.5962	0.0041	10.8903	31.5287	AID504467
NFKB1 protein, partial	Homo sapiens (human)	Potency	0.0282	0.0282	7.0559	15.8489	AID895; AID928
SMAD family member 3	Homo sapiens (human)	Potency	6.9167	0.1737	34.3047	61.8120	AID1346924
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.0386	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	7.8002	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID588515; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	50.1187	0.1000	22.9075	100.0000	AID485364
Smad3	Homo sapiens (human)	Potency	0.2239	0.0052	7.8098	29.0929	AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.0316	0.0013	7.7625	44.6684	AID914; AID915
progesterone receptor	Homo sapiens (human)	Potency	0.7048	0.0004	17.9460	75.1148	AID1346784; AID1347036
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.1457	0.0002	14.3764	60.0339	AID588532; AID720691; AID720692; AID720719
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.4216	0.0015	30.6073	15,848.9004	AID1224841; AID1259401
pregnane X nuclear receptor	Homo sapiens (human)	Potency	21.0819	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	6.1312	0.0002	29.3054	16,493.5996	AID743075; AID743078; AID743079; AID743080; AID743091
arylsulfatase A	Homo sapiens (human)	Potency	1.0691	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	29.7357	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.9485	0.0017	23.8393	78.1014	AID743083
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	0.0045	0.5406	17.6392	96.1227	AID2364; AID2528
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	75.6863	23.9341	23.9341	23.9341	AID1967
chromobox protein homolog 1	Homo sapiens (human)	Potency	44.6684	0.0060	26.1688	89.1251	AID488953
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.2514	0.0041	9.9848	25.9290	AID504444; AID720524
heat shock protein beta-1	Homo sapiens (human)	Potency	6.6819	0.0420	27.3789	61.6448	AID743210
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	3.7932	0.0006	27.2152	1,122.0200	AID743202; AID743219
geminin	Homo sapiens (human)	Potency	0.5623	0.0046	11.3741	33.4983	AID624297
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	19.9526	0.0316	10.2792	39.8107	AID884; AID885
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	1.1220	0.0041	9.9625	28.1838	AID2675
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0224	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Interferon beta	Homo sapiens (human)	Potency	7.4536	0.0033	9.1582	39.8107	AID1347407
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	0.0119	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	0.0119	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
procathepsin L isoform 1 preproprotein	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0016	3.9614	31.1549	AID1627; AID825
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0580	0.0000	0.4953	10.0000	AID625263
Glucocorticoid receptor	Homo sapiens (human)	Ki	0.0260	0.0001	0.3863	7.0010	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0580	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Ki	0.0260	0.0007	0.7653	7.0010	AID625263
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	9.4700	0.0000	2.8005	10.0000	AID1210069
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0580	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	Ki	0.0260	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0580	0.0015	0.8044	5.0740	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Ki	0.0260	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0580	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Ki	0.0260	0.0007	0.7846	7.0010	AID625263
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	9.4700	0.0120	2.5312	9.4700	AID1210069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
icosanoid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
regulation of heart contraction	Cytochrome P450 2J2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glycine receptor subunit beta	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID384955	Intrinsic aqueous solubility at pH 10 by shake-flask method	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Molecular characteristics for solid-state limited solubility.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID74376	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1210074	Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID188016	Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID39320	Relative binding affinity for androgen receptor of prostate of rat at 2 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID74377	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID346025	Binding affinity to beta cyclodextrin	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1656448	In vivo inhibition of beta-glucuronidase in OF1 mouse at 10 mg/kg, po after 8 days relative to control	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID507145	Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis	2008	Nature chemical biology, Jan, Volume: 4, Issue:1	Integrating high-content screening and ligand-target prediction to identify mechanism of action.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1769778	Chondro-protective activity in MIA-induced Sprague-Dawley rat osteoarthritis model assessed as reduction of cell loss at 0.06 mg, ia administered once per week for 3 weeks starting from 5 days post MIA treatment and measured after 26 days post MIA injecti	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1769779	Chondro-protective activity in MIA-induced Sprague-Dawley rat osteoarthritis model assessed as reduction of bone resorption in medial femoral condyle at 0.06 mg, ia administered once per week for 3 weeks starting from 5 days post MIA treatment and measure	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
AID126435	Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1769782	Chondro-protective activity in MIA-induced Sprague-Dawley rat osteoarthritis model assessed as reduction of osteophyte score at 0.06 mg, ia administered once per week for 3 weeks starting from 5 days post MIA treatment and measured after 26 days post MIA	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1769781	Chondro-protective activity in MIA-induced Sprague-Dawley rat osteoarthritis model assessed as reduction of bone resorption in tibia at 0.06 mg, ia administered once per week for 3 weeks starting from 5 days post MIA treatment and measured after 26 days p	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
AID1769780	Chondro-protective activity in MIA-induced Sprague-Dawley rat osteoarthritis model assessed as reduction of bone resorption in lateral femoral condyle at 0.06 mg, ia administered once per week for 3 weeks starting from 5 days post MIA treatment and measur	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
AID91224	Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311367	Permeability coefficient in human skin	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID310931	Partition coefficient, log P of the compound	2007	Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1132664	Glucocorticoid activity in sc dosed bilaterally adrenalectomized rat assessed as glycogen deposition in liver administered for 5 days relative to cortisol	1978	Journal of medicinal chemistry, May, Volume: 21, Issue:5	A Fujita--Ban structure--activity analysis of 44 steroids.
AID1210073	Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID507146	Inhibition of mitosis in human HeLa cells by imaging analysis	2008	Nature chemical biology, Jan, Volume: 4, Issue:1	Integrating high-content screening and ligand-target prediction to identify mechanism of action.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID74375	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID213396	Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1210071	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID310933	Permeability across PAMPA membrane after 7 hrs	2007	Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1210070	Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1210072	Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID74378	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID74373	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID162613	Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID74374	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID90104	Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346849	Human Glucocorticoid receptor (3C. 3-Ketosteroid receptors)	2000	The Journal of biological chemistry, Jun-23, Volume: 275, Issue:25	Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1900 (51.10)	18.7374
1990's	287 (7.72)	18.2507
2000's	552 (14.85)	29.6817
2010's	770 (20.71)	24.3611
2020's	209 (5.62)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	408 (9.96%)	5.53%
Reviews	229 (5.59%)	6.00%
Case Studies	785 (19.16%)	4.05%
Observational	18 (0.44%)	0.25%
Other	2,658 (64.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (480)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis [NCT02437461]	Phase 4	159 participants (Actual)	Interventional	2015-04-30	Active, not recruiting
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema [NCT00367133]	Phase 3	840 participants (Actual)	Interventional	2004-07-31	Completed
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular D [NCT05811351]	Phase 2	300 participants (Anticipated)	Interventional	2023-03-06	Recruiting
Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries [NCT05364099]	Phase 4	0 participants (Actual)	Interventional	2023-11-27	Withdrawn(stopped due to Unable to feasibly complete study.)
Clinical Evolution of Hemiparetic Shoulder Pain With a Capsular Pattern in a Subacute Stroke Population Following Physiotherapy Coupled With Cortisone Infiltration and Mild Arthrographic Distension Versus Physiotherapy Alone : A Pragmatic Study [NCT05845125]	Phase 4	50 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Double Blinded Prospective Pilot Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) vs. Standard of Care in Adhesive Capsulitis of the Shoulder [NCT05844930]	Phase 4	50 participants (Anticipated)	Interventional	2023-01-03	Recruiting
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis: a Non-inferiority Randomized Controlled Double-blind Study [NCT05806021]	Phase 4	327 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy [NCT01280214]		30 participants (Anticipated)	Interventional	2011-02-28	Not yet recruiting
Active Control,Randomized,Double- Blinded Clinical Trial of BD [NCT03771768]		38 participants (Anticipated)	Interventional	2019-05-25	Not yet recruiting
Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial [NCT05223244]	Phase 4	83 participants (Actual)	Interventional	2011-10-01	Completed
Physiotherapy Alone, in Combination With Corticosteroid Injection or Wait-and-see for Acute Lateral Epicondylitis in General Practice: a Randomised, Placebo-controlled Study With 12 Months Follow-up [NCT00826462]	Phase 4	177 participants (Actual)	Interventional	2009-03-31	Completed
The Efficacy of Topical Sesame Oil in Orabase Versus Topical Triamcinolone in Orabase on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker, Malondialdehyde [MDA] : Randomized Clinical Trial (RCT) [NCT03738176]	Early Phase 1	40 participants (Anticipated)	Interventional	2019-12-16	Not yet recruiting
Analysis of Antalgic Efficacy of an Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis by Perfusion MRI:a Superiority, Randomized, Controlled, Double Blind Study [NCT03726788]	Phase 2	105 participants (Anticipated)	Interventional	2019-09-30	Not yet recruiting
Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone [NCT03641508]	Phase 4	69 participants (Actual)	Interventional	2014-01-31	Completed
Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease [NCT01295099]	Phase 4	0 participants (Actual)	Interventional		Withdrawn
A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of t [NCT03382262]	Phase 2	55 participants (Actual)	Interventional	2017-12-18	Completed
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion [NCT01178697]	Phase 2	0 participants	Interventional	2010-01-31	Recruiting
A Randomized Phase II Double-Blinded Study of The Efficacy of Oleogel-S10 (AP101) Gel for the Treatment of Grade 2/3 Radiation Dermatitis in Breast Cancer Patients [NCT05190770]	Phase 2	50 participants (Anticipated)	Interventional	2021-12-15	Recruiting
Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery in Treating Refractory Granulomatous Lobular Mastitis: A Randomized Controlled Trial [NCT05281419]		100 participants (Anticipated)	Interventional	2022-05-01	Recruiting
The NOR-CACTUS Trial - A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome [NCT05306548]	Phase 4	258 participants (Anticipated)	Interventional	2022-04-08	Recruiting
Prospective And Randomized Study Evaluating Tthe Effect Of The Association Of Triamcinolone To The Viscosupplementation Of The Knee [NCT01335321]	Phase 4	108 participants (Actual)	Interventional	2011-03-31	Completed
Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema [NCT03126786]	Phase 2	71 participants (Actual)	Interventional	2017-07-11	Completed
[NCT02454088]		20 participants (Actual)	Interventional	2015-05-31	Completed
IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA [NCT02451748]	Phase 4	32 participants (Actual)	Interventional	2015-08-31	Completed
MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis [NCT02952001]		33 participants (Actual)	Observational	2017-12-13	Completed
Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis [NCT02399800]		1 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Low enrollment)
Comparing the Efficacy of Rotator Interval Steroid Injection Versus Steroid Intraarticular Hydrodilatation in the Treatment of Frozen Shoulder [NCT03678038]		64 participants (Actual)	Interventional	2018-09-28	Completed
Intralesional Injections of Triamcinolone for Acne Vulgaris [NCT06170593]		20 participants (Actual)	Interventional	2022-11-15	Completed
Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial [NCT04115644]	Phase 4	82 participants (Actual)	Interventional	2017-05-01	Terminated(stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018)
SAPPHIRE: A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Conjunction With Intravitreal Aflibercept In Subjects With Retinal Vein Occlusion [NCT02980874]	Phase 3	460 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.)
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy [NCT02329288]	Phase 3	60 participants (Anticipated)	Interventional	2015-05-31	Not yet recruiting
25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients [NCT02328118]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Efficacy of Holmium Laser Uretherotomy in Combination With Intralesional Steroids in the Treatment of Bulbar Uretheral Stricture [NCT05078788]		124 participants (Actual)	Interventional	2020-06-02	Completed
A Randomized, Double-Blind Study of the Efficacy of Platelet-Rich Growth Factor (PRGF) Supplementation Compared to Steroid Supplementation After Temporomandibular Joint (TMJ) Arthrocentesis in Female Patients With TMJ Osteoarthritis (OA) [NCT04731233]	Phase 4	36 participants (Anticipated)	Interventional	2021-03-30	Recruiting
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis [NCT03011892]	Phase 2	307 participants (Actual)	Interventional	2017-01-09	Completed
A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Combination With An Intravitreal Anti-VEGF Agent In Subjects With Retinal Vein Occlusion [NCT03203447]	Phase 3	325 participants (Actual)	Interventional	2018-03-05	Terminated(stopped due to The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint.)
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial [NCT04895280]	Phase 4	400 participants (Anticipated)	Interventional	2024-04-30	Not yet recruiting
Outcome Comparison of Ultrasound-guided Hydrodissection Between Normal Saline and Combination of Triamcinolone Acetonide, Normal Saline, and Lidocaine in Mild to Moderate Carpal Tunnel Syndrome: A Single Blinded Randomized Clinical Trial [NCT05577676]		62 participants (Anticipated)	Interventional	2022-09-13	Recruiting
A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients [NCT01356602]	Phase 3	397 participants (Actual)	Interventional	2011-05-31	Completed
Comparison of Total Knee Arthroplasties With Oxidized Zirconium and Cobalt Chromium Femoral Components in the Same Patients: A Prospective, Double Blinded, and Randomized Controlled Study [NCT01336595]	Phase 4	331 participants (Actual)	Interventional	2003-01-31	Completed
Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study. [NCT03640650]	Phase 4	80 participants (Actual)	Interventional	2018-08-15	Terminated(stopped due to COVID-19 pandemic leading to uncertainty in the recruitement)
Evaluation of Salivary Levels of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid [NCT03871114]		30 participants (Actual)	Observational	2019-03-10	Completed
A Comparative Study of Betamethasone (Diprospan) and Triamcinolone Acetonide as Single Intra-Articular Injection in Knee Osteoarthritis, A Double-Blinded, Randomized Controlled Trial [NCT05139875]	Phase 4	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation [NCT02653963]		106 participants (Actual)	Interventional	2014-09-30	Completed
Formulated Posterior Subtenon Triamcinolone (PSTA) Injection Versus Posterior Subtenon Triamcinolone Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions [NCT05385562]		78 participants (Actual)	Interventional	2020-01-02	Completed
Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis [NCT03097315]	Phase 3	38 participants (Actual)	Interventional	2017-04-04	Completed
A Randomized, Controlled, Double-blind Study to Evaluate the Efficacy of Intralesional Triamcinolone in the Treatment of Hidradenitis Suppurativa. [NCT02781818]		32 participants (Actual)	Interventional	2016-06-30	Completed
Intralesional Steroid Injection Versus Accent Method of Voice Therapy in Management of Vocal Nodules: A Randomized Controlled Trial [NCT03914092]	Phase 4	40 participants (Anticipated)	Interventional	2019-09-29	Recruiting
Effects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty: a Prospective Double-blinded Placebo Controlled Randomised Clinical Trial [NCT03901768]	Phase 4	180 participants (Anticipated)	Interventional	2018-04-26	Recruiting
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study [NCT00279916]	Phase 3	91 participants (Actual)	Interventional	2005-09-01	Completed
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion [NCT01044329]	Phase 2	90 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis [NCT03729310]	Early Phase 1	0 participants (Actual)	Interventional	2020-03-31	Withdrawn(stopped due to No participants enrolled)
Multi-Center, Randomized Controlled Trial Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis [NCT05526898]		176 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Randomized Single Blinded Prospective Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients [NCT03319784]	Phase 4	0 participants (Actual)	Interventional	2018-09-05	Withdrawn(stopped due to never initiated)
Eco-guided Treatment With Triamcinolone-Acetonide in the Treatment of Medial Plica Syndrome - A Pilot Study [NCT04943341]		30 participants (Anticipated)	Interventional	2021-10-28	Recruiting
Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial [NCT03535233]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
"Platelet-Rich Plasma Transforaminal Epidural Injection an Emerging Strategy in Lumbar Disc Herniation" [NCT05234840]		30 participants (Actual)	Interventional	2019-04-01	Completed
A Prospective Randomized Comparative Trial of Targeted Injection Via a Transforaminal Approach With Dexamethasone Versus an Epidural Catheter Via an Interlaminar Approach With Particulate Steroid for the Treatment of Cervical Radicular Pain [NCT03382821]	Phase 4	120 participants (Actual)	Interventional	2017-09-15	Completed
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in Patients With Neovascular Age-Related Macular Degeneration [NCT02457026]		0 participants (Actual)	Interventional	2016-01-31	Withdrawn
Therapeutic Effects of Knee Intra-articular Injections on Patients With Knee Osteoarthritis: a Double-blind, Randomized, Placebo-controlled Clinical Trial [NCT05220527]	Phase 4	60 participants (Anticipated)	Interventional	2020-08-01	Enrolling by invitation
Ketorolac Versus Triamcinolone Intra-articular Knee Injections for the Treatment of Osteoarthritis. A Prospective, Double-Blinded Randomized Trial [NCT02295189]		36 participants (Actual)	Interventional	2013-01-31	Completed
Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter [NCT03165344]		66 participants (Actual)	Interventional	2017-02-10	Completed
Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection [NCT03132051]		54 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) [NCT04460001]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2019-05-16	Recruiting
Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment [NCT03431961]		20 participants (Anticipated)	Interventional	2018-03-07	Recruiting
[NCT00849537]	Phase 1/Phase 2	0 participants	Interventional	2008-04-30	Recruiting
Efficacy of Oral Zinc Supplement as an Adjunctive Therapy for Erosive Oral Lichen Planus (a Randomized, Controlled Clinical Trial) [NCT06042010]		22 participants (Actual)	Interventional	2023-01-05	Completed
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo [NCT02191748]	Phase 2/Phase 3	22 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Principal investigator made the decision to close study and not submit a renewal. Lack of fixed research personnel to carry out the study effectively.)
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids [NCT02996097]		30 participants (Actual)	Interventional	2016-04-30	Completed
Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial [NCT04441112]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2018-05-20	Completed
Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis [NCT05005000]	Phase 2	1 participants (Actual)	Interventional	2022-05-12	Terminated(stopped due to Difficulties getting subjects recruited and enrolled.)
Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated With Retinal Vein Occlusion: A Pilot Study [NCT05038072]		16 participants (Actual)	Interventional	2019-07-25	Completed
A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus [NCT02762370]	Phase 2	33 participants (Actual)	Interventional	2016-04-30	Completed
Safety and Efficacy of Of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein In Acute Gout [NCT05925166]		100 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Comparing the Efficacy of Ultrasound Guided Hyaluronic Injection With Ultrasound Guided Corticosteroid Injection in Treatment of Trigger Finger [NCT03131882]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2016-10-01	Recruiting
Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation [NCT03473600]	Phase 4	40 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma [NCT03046108]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough [NCT04468542]	Phase 3	65 participants (Anticipated)	Interventional	2021-01-12	Recruiting
Evaluation of the Use of Intraoperative Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy During Bare Scleral Pterygium Excision [NCT03377348]		30 participants (Actual)	Interventional	2017-12-01	Completed
Efficacy of Neural Prolotherapy Versus Local Corticosteroid Soft Tissue Injection for Treatment of Anserine Bursitis [NCT04509440]		43 participants (Actual)	Interventional	2018-05-01	Completed
Intradetrusor Triamcinolone Injection in the Management of Interstitial Cystitis/Bladder Pain Syndrome: Pilot Study [NCT05226832]		0 participants (Actual)	Interventional	2022-08-31	Withdrawn(stopped due to Study never started.)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis [NCT02576938]	Phase 2	124 participants (Actual)	Interventional	2016-02-29	Completed
Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema [NCT01095809]	Phase 3	5 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to New intraocular steroid in the market. Recruitment no longer ethical.)
A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study of Once Daily Triamcinolone Acetonide 0.5% DuraPeel™ Versus Placebo DuraPeel in the Treatment of Hand Dermatitis [NCT00890968]	Phase 2	56 participants (Actual)	Interventional	2009-04-30	Completed
Triamcinolone Acetonide Injections Compared With Micro Injections (MMP Technique) of Triamcinolone Acetonide for the Treatment of Female Genital Lichen Sclerosus and Atrophic [NCT06079645]	Phase 4	20 participants (Anticipated)	Interventional	2023-10-20	Recruiting
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa [NCT04582669]	Phase 4	11 participants (Actual)	Interventional	2022-01-24	Terminated(stopped due to This study was administratively closed.)
Gene Expression and Biomarker Profiling of Keloid Skin [NCT03228693]		48 participants (Actual)	Interventional	2017-09-11	Completed
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide [NCT02294656]	Phase 1	4 participants (Actual)	Interventional	2014-11-30	Completed
Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial [NCT04961281]		60 participants (Actual)	Interventional	2021-07-22	Completed
Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata: a Pilot Study of Patient Tolerability [NCT05278858]	Phase 4	15 participants (Anticipated)	Interventional	2022-03-24	Recruiting
A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling [NCT03361176]	Phase 4	30 participants (Actual)	Interventional	2018-03-26	Completed
Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema [NCT02949024]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2016-11-10	Completed
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab [NCT01249937]	Phase 2	30 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Granulation Tissue at G Tube Site: Treatment With Kenalog vs Chemical Cauterization With Silver Nitrate vs Soap Washcloth Abrasion [NCT02519738]	Phase 3	52 participants (Actual)	Interventional	2015-01-15	Terminated(stopped due to enrollment difficulties)
The Effect of Topical Curcumin Versus Topical Corticosteroid on Pain, Clinical Parameters and Salivary Level of IL-33 in Oral Lichen Planus Patients: A Randomized Controlled Clinical Trial [NCT03877679]	Phase 1	40 participants (Anticipated)	Interventional	2019-05-01	Not yet recruiting
Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study [NCT06004882]		45 participants (Anticipated)	Interventional	2023-08-10	Recruiting
Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy [NCT01330524]	Phase 1/Phase 2	16 participants (Anticipated)	Interventional	2010-01-31	Recruiting
The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema [NCT00893854]	Phase 1	0 participants	Interventional		Recruiting
Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis [NCT01318590]	Phase 3	2 participants (Actual)	Interventional	2011-11-18	Terminated(stopped due to Closed by CHUM REB for incomplete documentation of research activities.)
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study [NCT04326959]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week D [NCT01029652]	Phase 3	230 participants (Actual)	Interventional	2009-12-31	Completed
A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma. [NCT02873026]	Phase 3	300 participants (Actual)	Interventional	2014-10-31	Completed
Arteriovenous Crossing Sheathotomy Versus Intravitreal Triamcinolone Acetonide Injection for Treatment of Macular Edema Associated With Branch Retinal Vein Occlusion [NCT00612261]		40 participants (Actual)	Interventional	2006-10-31	Completed
Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study [NCT00640575]		106 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema [NCT00737971]	Phase 4	142 participants (Actual)	Interventional	2008-08-31	Completed
Evaluation of the Role of Local Steroid Injection in Treatment of Idiopathic Spasmodic Flat Foot in Adolescent Patients [NCT05381558]		20 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae [NCT00757315]		20 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results [NCT05337332]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis: A Clinical Trial [NCT05660694]	Phase 4	40 participants (Actual)	Interventional	2020-01-01	Completed
Rotator Interval and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial [NCT00840229]		122 participants (Actual)	Interventional	2009-02-28	Completed
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial [NCT02858297]	Phase 4	30 participants (Actual)	Interventional	2015-05-31	Completed
Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy [NCT02806752]	Phase 4	120 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
The Evaluation of Effect of the Cervical İnterlaminar Epidural Steroid İnjection on Quality of Life, Neuropathic Pain and Disability in Patients With Cervical Radiculopathy [NCT04235478]		78 participants (Actual)	Interventional	2017-12-27	Active, not recruiting
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study [NCT02221453]	Phase 2	3 participants (Actual)	Interventional	2015-09-30	Completed
Randomized Clinical Trial Comparing Silver Nitrate Application With Topical Corticosteroids for Hypergranulation Tissue at Gastrostomy Sites [NCT02398539]	Phase 4	50 participants (Anticipated)	Interventional	2015-04-30	Recruiting
One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases [NCT05496530]		100 participants (Anticipated)	Interventional	2022-07-10	Recruiting
Comparative Study on the Efficacy of Periocular Methotrexate Versus Periocular Triamcinolone Injections in Management of Thyroid Associated Orbitopathy [NCT05429450]	Phase 2	18 participants (Actual)	Interventional	2020-07-01	Completed
Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study [NCT02155439]	Phase 4	50 participants (Actual)	Interventional	2014-05-31	Completed
Symptom Clusters in Children With Exacerbation-prone Asthma [NCT04002362]	Phase 2	173 participants (Anticipated)	Interventional	2019-11-13	Recruiting
The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children [NCT04524897]	Phase 4	20 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study [NCT03572959]	Phase 4	24 participants (Actual)	Interventional	2016-12-27	Completed
Alazher University Dean [NCT05464953]		75 participants (Actual)	Interventional	2020-01-20	Completed
Comparison of Triamcinolone Acetonide Mucoadhesive Film With Liquorice Mucoadhesive Film On Radiotherapy-Induced Oral Mucositis: A Randomized Double-Blinded Clinical Trial [NCT02075749]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2013-05-31	Completed
Methotrexate With Microneedling Versus Triamcinilone Acetonide With Microneedling in Treatment of Recalcitrant Alopecia Areata [NCT06088147]		34 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis [NCT04976816]	Phase 2/Phase 3	92 participants (Actual)	Interventional	2021-12-01	Completed
Viscosupplementation in Patients With Severe Osteoarthritis of the Knee [NCT03090698]	Phase 4	120 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Comparison of Different Dose of Steroid Injection in Carpal Tunnel Syndrome [NCT03072290]		56 participants (Actual)	Interventional	2017-02-18	Completed
Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Ana [NCT04991012]	Phase 2	30 participants (Actual)	Interventional	2020-02-08	Completed
A Randomized, Double-blind Comparison Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat [NCT03241563]	Phase 4	20 participants (Actual)	Interventional	2016-04-30	Completed
Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm：a Randomized Controlled Trial [NCT03039608]		72 participants (Actual)	Interventional	2017-02-10	Completed
A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis [NCT02595398]	Phase 3	160 participants (Actual)	Interventional	2015-11-17	Completed
OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy [NCT04075136]	Phase 4	150 participants (Anticipated)	Interventional	2023-03-30	Suspended(stopped due to Deviations)
Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial. [NCT05624866]		60 participants (Anticipated)	Interventional	2022-10-10	Recruiting
Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study [NCT05349448]	Early Phase 1	100 participants (Anticipated)	Interventional	2022-03-28	Recruiting
Safety and Effectiveness of Triamcinolone Acetonide in Patients With Serous Pigment Detachment Associated With Age-Related Macular Degeneration [NCT04292756]		63 participants (Actual)	Interventional	2018-03-27	Completed
Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome [NCT02870738]	Phase 2	128 participants (Anticipated)	Interventional	2017-04-21	Recruiting
Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery [NCT02917564]	Phase 4	20 participants (Anticipated)	Interventional	2020-10-14	Recruiting
Efficacy Of Intralesional Injection Of Methotrexate Versus Triamcinolone Acetonid In Treatment Of Localized Psoriasis [NCT05408208]		30 participants (Anticipated)	Interventional	2022-05-21	Recruiting
Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata [NCT04003376]	Phase 4	40 participants (Anticipated)	Interventional	2019-07-26	Recruiting
A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial [NCT00398866]	Phase 3	200 participants (Actual)	Interventional	2006-08-31	Completed
A Comparison of a Single Orbital Floor Injection of Triamcinolone Versus Conventional Steroid and Antibiotic Drops Used Post Operatively in Uneventful Phacoemulsification Surgery [NCT00789971]		150 participants (Actual)	Interventional	2007-03-31	Completed
Comparison Of Greater Occipital Nerve Block With Lidocaine And Bupivicaine Alone Or With Steroids In a Chronic Headache Population [NCT00203294]		45 participants (Actual)	Interventional	2005-06-30	Completed
An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colch [NCT00798369]	Phase 2	200 participants (Actual)	Interventional	2008-11-30	Completed
Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial [NCT02823236]	Phase 3	102 participants (Anticipated)	Interventional	2016-10-24	Recruiting
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis. [NCT05906433]	Phase 1	75 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Open Label Prospective Trial of Fractional Ablative CO 2 Resurfacing With Laser- Facilitated Steroid Delivery in Patients With Mild to Moderate Hidradenitis Suppurativa. [NCT05580029]	Early Phase 1	10 participants (Anticipated)	Interventional	2022-11-01	Not yet recruiting
Influence of Perception of Patients Suffering of Osteoarthritis of Knee Over the Effectiveness and Tolerance in Intra-articular Injection of Corticoids: a Prospective, Controlled and Randomized Study [NCT02835521]	Phase 4	100 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees [NCT02829281]	Phase 4	105 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Ultrasonographic Evaluation of the Effectiveness of Stellate Ganglion Block in Patients With Breast Cancer Related Lymphedema [NCT04165512]		22 participants (Anticipated)	Interventional	2020-01-07	Enrolling by invitation
Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain [NCT02748395]	Phase 4	0 participants (Actual)	Interventional	2016-05-31	Withdrawn(stopped due to No IRB approval)
Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial With Immunohistochemical Analysis [NCT05882864]	Phase 4	28 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis [NCT03390036]	Phase 3	526 participants (Actual)	Interventional	2017-12-07	Completed
Evaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen Planus (A Randomized Controlled Clinical Trial) [NCT05951361]		44 participants (Actual)	Interventional	2022-02-01	Completed
Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial [NCT02461368]		50 participants (Actual)	Interventional	2012-12-31	Completed
Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction [NCT01051648]	Phase 2	10 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00987233]	Phase 3	0 participants	Interventional		Completed
Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema [NCT00444600]	Phase 3	691 participants (Actual)	Interventional	2007-03-31	Completed
The Role of Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Middle Meatal Spacer Following Endoscopic Sinus Surgery: A Randomized, Double-Blind, Placebo Controlled Trial [NCT01564355]		80 participants (Actual)	Interventional	2012-04-30	Completed
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields [NCT04469075]	Phase 2	58 participants (Anticipated)	Interventional	2020-07-09	Recruiting
[NCT00685100]	Phase 3	40 participants	Interventional	2004-01-31	Completed
Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis [NCT00742846]		0 participants (Actual)	Interventional	2008-08-31	Withdrawn(stopped due to No enrollment)
Incidence of Flare Reaction Following Shoulder Steroid Injections: Comparison of Depo-medrol (Methylprednisolone) and Kenalog (Triamcinolone) [NCT05438277]	Phase 4	421 participants (Actual)	Interventional	2020-01-01	Completed
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption [NCT03115567]	Phase 2	14 participants (Actual)	Interventional	2017-02-16	Terminated(stopped due to Low enrollment accrual)
The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. [NCT02618603]	Phase 4	50 participants (Anticipated)	Interventional	2016-02-29	Not yet recruiting
Prospective Randomize Trial Comparing Corticosteroid Injection to High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis [NCT02613455]	Phase 4	80 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Pilot Study of Transforaminal Epidural Injection of Clonidine for the Treatment of Acute Lumbosacral Radiculopathy [NCT00588354]		26 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Targeted enrollment was not reached.)
Prospective Randomized Controlled Clinical Trial: Superior Hypogastric Nerve Block for Pain Control After Uterine Artery Embolization: Effect of Addition of Steroids on Duration of Analgesia [NCT04126824]	Early Phase 1	28 participants (Anticipated)	Interventional	2019-11-05	Recruiting
Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee [NCT00731289]	Phase 4	60 participants (Actual)	Interventional	2003-07-31	Completed
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy [NCT00445003]	Phase 3	333 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema [NCT00682539]	Phase 4	71 participants (Actual)	Interventional	2007-10-31	Completed
Triamcinolone Ketorolac (TriKe) Knee Trial Evaluating the Effectiveness and Possible Superiority of Ketorolac vs. Cortisone When Injected Intra-Articular in Subjects With Osteoarthrosis [NCT05336968]	Phase 4	150 participants (Anticipated)	Interventional	2022-09-15	Enrolling by invitation
A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema [NCT00924508]		23 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Loss of Funding)
Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Diabetic Retinopathy [NCT00806169]	Phase 3	40 participants (Actual)	Interventional	2006-04-30	Completed
Resistant Diabetic Macular Edema and Suprachoroidal Injection [NCT04690608]	Early Phase 1	100 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure [NCT00665977]	Phase 3	44 participants (Anticipated)	Interventional	2007-09-30	Completed
Treatment of Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone and Laser Photocoagulation: Randomized Clinical Trial With Morphological and Functional Evaluation [NCT00668239]		14 participants (Actual)	Interventional	2004-09-30	Completed
Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema. [NCT00874744]	Phase 2	13 participants (Actual)	Interventional	2008-03-31	Completed
Efficacy and Safety of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: A Prospective, Randomized, Double-blind, Placebo-controlled Study [NCT01246284]		5 participants (Actual)	Interventional	2010-12-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adr [NCT01154153]	Phase 4	140 participants (Actual)	Interventional	2010-06-30	Completed
Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment [NCT00167518]	Phase 2/Phase 3	70 participants	Interventional	2002-03-31	Completed
Efficacy of Dextrose Injections, Corticosteroids Injections and Surgical Release for Treatment of the Carpal Tunnel Syndrome: a Prospective, Randomized, Double-blind Controlled Trial [NCT04014244]		100 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis [NCT02702206]		207 participants (Actual)	Interventional	2014-08-31	Completed
Efficacy of Post-Surgical Intralesional Injection With Triamcinolone Versus Triamcinolone Plus Fluorouracil in the Treatment of Keloids [NCT04710719]		7 participants (Actual)	Interventional	2021-02-01	Completed
Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema [NCT00309192]	Phase 3	292 participants (Anticipated)	Interventional	2006-04-30	Completed
Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis [NCT01385527]		0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to study was never initiated, No participants enrolled)
Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout [NCT03636373]	Phase 4	5 participants (Actual)	Interventional	2019-10-25	Terminated(stopped due to The Sponsor has decided to stop funding this study due to lack of enrollment during COVID-19 pandemic and decreased interest in funding investigator initiated studies pertaining to the study drug)
Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye [NCT01404364]		36 participants (Actual)	Interventional	2010-01-31	Completed
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids [NCT00846625]	Phase 2	0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to Insufficient enrollment (no subjects were enrolled))
VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema [NCT00764244]	Phase 3	72 participants (Actual)	Interventional	2005-01-31	Completed
Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) [NCT00997191]	Phase 3	12 participants (Actual)	Interventional	2009-10-31	Completed
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination Treatment of Crisaborole Ointment, 2% and a Concomitant Topical Corticosteroid Over a 8 Week Period [NCT04008784]		16 participants (Actual)	Observational	2019-09-16	Completed
A Multi-Center, Open-label, 24-week Clinical Investigation to Evaluate Safety and Tolerability of Treatment With the Oxulumis®, Suprachoroidal Drug Administration Device Delivering 2.4mg Triesence® With Diabetic Macular Edema [NCT05172401]		0 participants (Actual)	Interventional	2022-09-15	Withdrawn(stopped due to unforeseen, continued (>12month) global shortage of study medication. Study Drug Triesence, manufacturer Novartis, not supplied throughout 2022)
Combined Phacoemulsification Surgery and Intravitreal Triamcinolone Injection Versus Stand-alone Surgery in Patients With Type 2 Diabetes: A Randomized Controlled Trial [NCT05413330]	Phase 2/Phase 3	73 participants (Actual)	Interventional	2020-09-12	Completed
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations [NCT01073995]	Phase 3	54 participants (Actual)	Interventional	2010-03-31	Completed
Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat [NCT00908817]		150 participants (Actual)	Interventional	2008-05-31	Completed
A Phase IIb, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Helical Triamcinolone Acetonide Implant (MK0140) in Diabetic Patients With Clinically Significant Macular Edema [NCT00692614]	Phase 2	2 participants (Actual)	Interventional	2008-06-30	Terminated
A Randomized Parallel, Masked to Evaluate the Efficacy of Triamcinolone Associated With Nepafenac (Nevanac) Compared With Intravitreal Injection of Triamcinolone for Treatment of Clinically Significant Diabetic Macular Edema [NCT00780780]	Phase 3	40 participants (Actual)	Interventional	2007-07-31	Completed
Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfove [NCT00930189]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Treatment of Subacromial Shoulder Pain by Individual or Group Physiotherapy Following Corticosteroid Injection [NCT04058522]		136 participants (Actual)	Interventional	2008-09-19	Completed
Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration [NCT00464347]	Phase 2	100 participants (Anticipated)	Interventional	2007-01-31	Terminated(stopped due to Study was terminated because of poor enrollment.)
Injection Treatment of Slow-Release Corticosteroid to the Sacrospinous Ligament Insertions on Women With Long-Lasting Low Back Pain Starting in Pregnancy. [NCT00757016]		38 participants (Actual)	Interventional	2004-10-31	Completed
[NCT00801450]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2007-09-30	Active, not recruiting
Comparison Between Steroid and Two Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized Double-blind Active Drug-controlled Pilot Study [NCT02767635]	Phase 3	90 participants (Anticipated)	Interventional	2012-01-31	Recruiting
The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Osteoarthritis Research Society International (OARSI) Recommended Physical Performance Measures in Adults With Knee Osteoarthritis [NCT03895840]	Phase 4	70 participants (Actual)	Interventional	2018-03-19	Completed
Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. [NCT00811200]	Phase 2/Phase 3	220 participants (Anticipated)	Interventional	2009-09-30	Not yet recruiting
Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation [NCT00779792]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) [NCT02598869]	Phase 4	0 participants (Actual)	Interventional	2015-11-30	Withdrawn
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases [NCT00623766]	Phase 2	99 participants (Actual)	Interventional	2008-07-31	Completed
Role of Conditioning in the Pharmacotherapy of Psoriasis [NCT00005922]		138 participants (Actual)	Interventional	2000-08-31	Completed
Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy [NCT00391144]	Phase 2/Phase 3	5 participants	Interventional	2006-07-31	Recruiting
Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion [NCT00805064]	Phase 3	40 participants (Actual)	Interventional	2006-01-31	Completed
A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection [NCT02939482]		112 participants (Actual)	Interventional	2016-10-01	Completed
Phase II/III Multicentre Randomised Clinical Trial of Laser Treatment Plus 4 mg Intravitreal Triamcinolone Injection to Reduce Diabetic Macular Oedema [NCT00148265]	Phase 2/Phase 3	54 participants (Actual)	Interventional	2005-04-30	Completed
Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy [NCT05292339]	Phase 4	160 participants (Anticipated)	Interventional	2023-01-31	Recruiting
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata [NCT00999869]		20 participants (Anticipated)	Interventional	2009-11-30	Recruiting
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [NCT00369486]	Phase 2	113 participants (Actual)	Interventional	2004-12-31	Completed
Circumcision Versus Preputioplasty for BXO in Children: A Feasibility Randomised Controlled Trial [NCT02854995]		20 participants (Actual)	Interventional	2016-10-01	Completed
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata [NCT00484679]	Phase 2	18 participants (Actual)	Interventional	2007-05-31	Completed
Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement [NCT03982862]	Phase 4	20 participants (Anticipated)	Interventional	2018-07-30	Recruiting
Randomized Controlled Trial of Endoscopic Dilation With or Without Triamcinolone Injection in Patients With Non-malignant Radiation or Anastomotic Esophageal Strictures [NCT01873573]		10 participants (Actual)	Interventional	2013-07-18	Completed
Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial [NCT01906944]	Phase 2	62 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer [NCT00473083]	Phase 2	150 participants (Actual)	Interventional	2009-01-31	Completed
Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy [NCT00411333]	Early Phase 1	100 participants (Anticipated)	Interventional	2006-07-31	Completed
Analgesic Effects of Trigger Point Injection Added to Caudal Epidural Steroid [NCT05792111]	Phase 4	72 participants (Anticipated)	Interventional	2022-10-12	Recruiting
Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial [NCT01766609]	Phase 2	18 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Steroid Versus Hyaluronic Acid Ultrasound-guided Injection for Trigger Finger: A Comparative Study of Outcomes [NCT01950793]		36 participants (Actual)	Interventional	2012-11-30	Completed
Intralesional Vitamin D3 Injection in Treatment of Alopecia Areata: A Novel Approach [NCT04660786]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Ultrasound-Guided Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger: Randomized Controlled Study [NCT04645303]	Early Phase 1	100 participants (Anticipated)	Interventional	2020-11-06	Recruiting
[NCT01961752]		111 participants (Actual)	Interventional	2012-07-31	Completed
A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials [NCT01978301]	Phase 1	9 participants (Actual)	Interventional	2014-04-15	Terminated(stopped due to Temporary hold on recruitment during staff changes at the site)
Open-Label, Parallel-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Corticosteroid Intra Articular Injection Given 7 Days Before or 7 Days After Lorecivivint Intra-articular Injection Into the Knee of Healthy Volunteers [NCT04598542]	Phase 1	40 participants (Actual)	Interventional	2020-10-13	Completed
Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion [NCT00566761]	Phase 4	10 participants (Anticipated)	Interventional	2007-06-30	Recruiting
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]		40 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Randomized Controlled Trial of Triamcinolone Impregnated Hemostatic Bioabsorbable Middle Meatus Nasal Packing Following Endoscopic Sinus Surgery [NCT04841343]		22 participants (Actual)	Observational [Patient Registry]	2021-01-29	Completed
Randomized Clinical Control Trial Comparing the Effects of a Steroid Eluting Implant Versus Triamcinolone-impregnated Carboxymethylcellulose Foam on the Postoperative Clinic Experience in Patients That Underwent Functional Endoscopic Surgery for Nasal Pol [NCT03607175]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2023-07-24	Not yet recruiting
Comparative Effectiveness of Particulate Versus Nonparticulate Corticosteroid Injections for the Treatment of Musculoskeletal Conditions [NCT04278833]	Phase 4	198 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Efficacy and Safety of Intralesional Triamcinolone Acetonide Alone and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars [NCT04812626]		66 participants (Actual)	Interventional	2021-01-28	Completed
Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections [NCT02022722]	Phase 4	36 participants (Anticipated)	Interventional	2013-08-31	Recruiting
A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee [NCT02022930]	Phase 3	510 participants (Anticipated)	Interventional	2014-01-31	Completed
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study [NCT02025023]	Phase 3	120 participants (Anticipated)	Interventional	2013-12-31	Recruiting
A Randomized Single-blinded Clinical Trial of the Efficacy of Intra-articular Infiltration of Cingal (Sodium Hyaluronate/Triamcinolone) Versus Cortisone (Triamcinolone) in Patients With Osteoarthritis of the Shoulder. [NCT05408065]		84 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater [NCT02031367]	Early Phase 1	50 participants (Anticipated)	Interventional	2014-03-31	Not yet recruiting
The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial [NCT05939817]	Phase 4	24 participants (Actual)	Interventional	2021-10-01	Completed
The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study [NCT00565019]	Phase 3	51 participants (Actual)	Interventional	2007-11-30	Completed
A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness [NCT00583271]		127 participants (Actual)	Observational	2002-06-30	Completed
Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial [NCT01874574]	Phase 4	100 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Including a 12 Weeks Extension Study [NCT01080131]	Phase 3	226 participants (Actual)	Interventional	2010-03-31	Completed
Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis in Patients Fifty Years and Older: a Look at Pain and Functional Outcomes at a Single Institution. [NCT06032039]	Early Phase 1	160 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial [NCT06135259]	Phase 3	18 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema Following Plaque Radiotherapy for Uveal Melanoma [NCT00441662]		170 participants	Interventional	2004-11-30	Completed
The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery [NCT00853905]	Phase 2/Phase 3	77 participants (Actual)	Interventional	2009-02-28	Completed
Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome [NCT02708693]		52 participants (Actual)	Interventional	2013-04-30	Completed
Project Arthritis Recovering Quality of Life Through Education - Hip [NCT04018690]		48 participants (Anticipated)	Interventional	2019-09-01	Not yet recruiting
Pilot Study of Chinese Medicine Medicated Bath as Complementary Medicine for Mild to Moderate Plaque -Type Psoriasis Patient. [NCT04117919]	Phase 2	30 participants (Anticipated)	Interventional	2019-10-05	Recruiting
The Effect of Ethosomal Gel Bearing Losartan 5% on The Patient and Observer Scar Assessment Scale Score, Degree of Erythema and Pigmentation, Surface Area, Thickness and Pliability of Human Keloids [NCT05893108]	Phase 1/Phase 2	46 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial [NCT02655523]	Phase 4	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to lack of recruitment)
Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis [NCT03586687]	Phase 4	19 participants (Actual)	Interventional	2018-07-13	Terminated(stopped due to insufficient rate of accrual)
Addition of a Topical Steroid to a Topical Retinoid: a Randomized, Split-face, Placebo-controlled, Double-blind, Single-center Clinical Study [NCT02704507]		20 participants (Actual)	Interventional	2015-06-30	Active, not recruiting
Assessment of the Effectiveness of Ultrasound-guided Acupuncture in the Management of Carpal Tunnel Syndrome [NCT02870673]	Phase 2/Phase 3	72 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
A Randomized Study Comparing Combined Vitrectomy and Triamcinolone to Laser Grid in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) [NCT00642226]	Phase 3	34 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and dexamethasone implant).)
Clinical Trials in Stroke Rehabilitation [NCT00597766]	Phase 2	28 participants (Actual)	Interventional	2007-12-31	Completed
Randomized Trial on the Evaluation of the Effectiveness of One Single Bone Marrow Aspirate Hip Injection Versus Triamcinolone for Hip Osteoarthritis [NCT04990128]	Phase 3	100 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Multi-Center, Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants With Neovascular Age-Related Macular Degeneration [NCT00100009]	Phase 3	30 participants	Interventional	2004-12-09	Completed
A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study [NCT00532142]	Phase 2/Phase 3	0 participants	Interventional	2005-04-30	Completed
Effect of Intracameral Steroids Injection During Phacoemulsification on Postoperative Corneal Edema and Corneal Endothelium [NCT05271058]	Phase 3	69 participants (Actual)	Interventional	2019-06-16	Completed
Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery [NCT00431028]	Phase 1/Phase 2	140 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to Terminated)
Medicated Punctured-Glove-Finger Spacer Study [NCT01420471]	Phase 4	50 participants (Actual)	Interventional	2011-09-30	Completed
Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin). [NCT00717652]	Phase 2/Phase 3	110 participants (Anticipated)	Interventional	2008-07-31	Suspended
A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO) [NCT01429870]	Phase 4	0 participants (Actual)	Interventional	2011-08-31	Withdrawn(stopped due to Lack of recruitment)
Phase I/II Study of Intravitreal Triamcinolone Acetonide Microspheres for Treatment of Diffuse Diabetic Macular Edema Unresponsive to Conventional Laser Photocoagulation Treatment. [NCT00407849]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2006-10-31	Active, not recruiting
Comparative Study Between Intralesional Autologous Platelet Rich Plasma and Intralesional Triamcinolone Acetonide in the Oral Erosions of Pemphigus Vulgaris Patients [NCT02828163]	Phase 3	11 participants (Actual)	Interventional	2016-01-31	Completed
Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis: A Randomized Clinical Trial [NCT00554476]	Phase 4	50 participants	Interventional	2003-01-31	Terminated(stopped due to Because the sample volume was completed during three years.)
The Role of Triamcinolone Injection During Cataract Extraction for Diabetic Patients With Pre-Operative Macular Edema [NCT00229931]		11 participants (Actual)	Interventional	2005-11-30	Completed
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD) [NCT00211419]	Phase 1	0 participants	Interventional		Completed
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose [NCT01851278]		60 participants (Anticipated)	Interventional	2013-04-30	Recruiting
PRevention of Macular EDema After Cataract Surgery [NCT01774474]	Phase 3	1,127 participants (Actual)	Interventional	2013-07-10	Completed
Additive Effects of Hyaluronidase in Intra-articular Steroid Injection Treating the Initial Stage of Adhesive Capsulitis for Shoulder [NCT04347733]	Phase 3	30 participants (Actual)	Interventional	2017-05-02	Completed
Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema [NCT02556424]	Phase 3	114 participants (Actual)	Interventional	2016-01-31	Completed
A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults [NCT00344942]	Phase 3	77 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to patient's recruitment too difficult)
Intracameral Use of Triamcinolone and Gatifloxacin Versus Standard Postoperative Steroid and Antibiotic Eye Drops After Cataract Surgery [NCT00478764]		41 participants (Actual)	Interventional	2006-03-31	Completed
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection [NCT00491712]		49 participants (Actual)	Interventional	2005-09-30	Active, not recruiting
Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema [NCT00476918]	Phase 1	60 participants (Anticipated)	Interventional	2006-07-31	Recruiting
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone [NCT04744623]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2020-09-30	Active, not recruiting
[NCT00523406]	Phase 3	40 participants (Actual)	Interventional	2005-08-31	Completed
Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery [NCT00532415]	Phase 3	60 participants (Actual)	Interventional	2007-09-30	Completed
An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis [NCT02465606]	Phase 2	55 participants (Actual)	Interventional	2015-07-30	Completed
Biological Response to Platelet-rich Plasma and Corticosteroid Injections [NCT05657496]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2022-12-28	Recruiting
[NCT00370266]	Phase 2	30 participants (Anticipated)	Interventional	2003-02-28	Completed
[NCT00370422]	Phase 3	0 participants	Interventional	2005-11-30	Active, not recruiting
A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus [NCT00242580]	Phase 3	111 participants (Actual)	Interventional	2005-09-30	Completed
Intra-articular Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain: a Multicentric, Double Blind Randomised, Versus Steroid Study [NCT01473277]	Phase 2	52 participants (Anticipated)	Interventional	2012-01-31	Not yet recruiting
Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema [NCT00229918]	Phase 2	60 participants	Interventional	2005-09-30	Recruiting
Efficacy of Ultrasound-Guided Deep Perineural Platelet Rich Plasma Versus Corticosteroid Injection in Patients With Ulnar Neuropathy at Elbow, a Comparative Study [NCT05567081]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2021-06-01	Completed
Evaluation of the Effect of Triamcinolone at Different Doses on Local Infiltration Anesthesia During Total Knee Arthroplasty [NCT05997238]		90 participants (Anticipated)	Observational	2023-04-25	Recruiting
The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids [NCT01435707]		125 participants (Actual)	Interventional	2011-09-30	Completed
Dropless Pars Plana Vitrectomy Study [NCT05331664]	Phase 4	168 participants (Anticipated)	Interventional	2022-07-25	Recruiting
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema [NCT00105404]	Phase 3	5 participants	Interventional	2005-03-09	Completed
Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy [NCT00443521]	Phase 2/Phase 3	30 participants	Interventional	2005-03-31	Completed
Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration [NCT00447031]		0 participants (Actual)	Interventional	2007-03-31	Withdrawn(stopped due to Insufficient patients who met inclusion criteria)
Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial. [NCT00148551]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2004-01-31	Active, not recruiting
Comparison of the Short-term Clinical Effects of Anterior Extra-articular and Posterior Intra-articular Administration of Ultrasound-guided Steroid Injection in the Treatment of Adhesive Capsulitis. A Prospective, Randomized and Single-blind Study [NCT05668286]		50 participants (Anticipated)	Interventional	2023-05-24	Recruiting
Additional Therapeutic Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial [NCT02949466]	Phase 4	56 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
PRESSURE: Prospektive, Randomisierte Und Kontrollierte Untersuchung Von Lokaler Druckapplikation im Rahmen Der Keloid-Therapie Der Ohrmuschel [NCT02962518]		18 participants (Actual)	Interventional	2014-07-31	Completed
Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema [NCT00468351]	Phase 1	0 participants	Interventional	2006-04-30	Active, not recruiting
Comparison of Perioperative Outcome Between Corticosteroids and Placebo in Transforaminal Endoscopic Lumbar Discectomy. A Single-center Randomized Placebo-controlled Trial. [NCT03273036]	Phase 4	30 participants (Actual)	Interventional	2014-05-01	Completed
[NCT00600301]	Phase 3	0 participants	Interventional		Recruiting
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca [NCT01670539]		47 participants (Actual)	Interventional	2011-04-30	Completed
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12) [NCT05436535]	Phase 4	600 participants (Anticipated)	Interventional	2022-11-21	Recruiting
Ultrasound-guided Glenohumeral Versus Subacromial Steroid Injections for Impingement Syndrome With Mild Stiffness: A Randomized Controlled Trial [NCT06051370]		51 participants (Actual)	Interventional	2013-01-12	Completed
Heated Lidocaine Patch Compared to Subacromial Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome, A Pilot [NCT01544283]	Phase 2	60 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Comparison of Topical Tacrolimus, Triamcinolone and Placebo in the Treatment of Symptomatic Oral Lichen Planus [NCT01544842]		28 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to Lack of resources)
Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders [NCT00101764]	Phase 1	120 participants	Interventional	2005-01-05	Completed
The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study [NCT00106132]	Phase 3	1,260 participants	Interventional	2005-03-31	Completed
The Chronic Obstructive Pulmonary Disease Early Intervention Trial [NCT00000569]	Phase 3	1,116 participants (Actual)	Interventional	1993-09-30	Completed
Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders [NCT00071227]	Phase 1	16 participants	Interventional	2003-10-15	Completed
A Randomized, Intraindividual, Phase 4 Study to Evaluate the Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects With Atopic Dermatitis [NCT05844618]	Phase 4	20 participants (Anticipated)	Interventional	2023-05-09	Recruiting
Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on t [NCT00021294]	Phase 2	0 participants	Interventional	2001-05-31	Completed
Assistant Professor, Ophthalmology Department, Al Azhar University [NCT05428683]		84 participants (Actual)	Interventional	2020-12-03	Completed
An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis [NCT00132925]	Phase 3	460 participants	Interventional	2003-11-30	Completed
An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment [NCT00148330]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2005-05-31	Completed
[NCT00370630]	Phase 2	15 participants	Interventional	2006-08-31	Recruiting
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis [NCT04182672]	Phase 2	22 participants (Actual)	Interventional	2020-08-12	Active, not recruiting
"NEUROIMPA Intraarticular Application of Opioids in Chronic Arthritis" [NCT02967302]	Phase 2/Phase 3	112 participants (Anticipated)	Interventional	2015-08-31	Active, not recruiting
Injection After Arthroscopic Partial Meniscectomy [NCT04641351]	Phase 4	150 participants (Anticipated)	Interventional	2021-05-27	Enrolling by invitation
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis: A Double-Blind Prospective Randomized Clinical Trial [NCT04002037]	Phase 4	120 participants (Actual)	Interventional	2019-06-25	Terminated(stopped due to Preliminary analysis revealed no difference)
Using Saline for Myofascial Pain Syndromes (USAMPS) [NCT02120261]	Phase 4	51 participants (Actual)	Interventional	2014-05-31	Terminated(stopped due to lack of activity, Primary researcher moved to another institution)
Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema [NCT02985619]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2016-07-21	Completed
Identifying Variables Associated With Steroid-Induced Hyperglycemia Following Intra-articular Knee Injections Among Diabetic Patients [NCT04317404]		11 participants (Actual)	Observational	2020-11-01	Completed
The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery [NCT01995045]	Phase 4	58 participants (Actual)	Interventional	2012-07-31	Completed
The Safety and the Efficacy of Combined Vitrectomy, Intravitreal Triamcinolone Acetonide and Macular Focal Laser Photocoagulation for the Treatment of Intractable Diffuse Diabetic Macular Edema [NCT00371410]	Phase 1	0 participants	Interventional	2005-04-30	Completed
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear [NCT01692756]	Phase 2	49 participants (Actual)	Interventional	2013-03-31	Completed
Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial. [NCT02024724]	Phase 4	60 participants (Actual)	Interventional	2013-11-30	Completed
Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial [NCT03958344]	Phase 3	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Multicenter, PrOspective, Randomized, Controlled Trial Comparing GenIcular Artery EmbOlization Using Embosphere Microspheres to Corticosteroid iNjections for the Treatment of Symptomatic Knee Osteoarthritis: MOTION Study [NCT05818150]		264 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [NCT00231023]	Phase 2	10 participants	Interventional	2005-09-30	Completed
Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema [NCT00915837]	Phase 1	31 participants (Actual)	Interventional	2005-06-30	Completed
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors [NCT03627741]	Phase 1	10 participants (Actual)	Interventional	2018-06-07	Completed
Comparative,Randomized Study Between Intravitreal Triamcinolone Acetonide and Air-Fluid Exchange in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage [NCT00300014]		30 participants (Anticipated)	Interventional	2006-01-31	Recruiting
Neovascular Age Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy [NCT00305630]	Phase 2/Phase 3	100 participants	Interventional	2002-07-31	Completed
[NCT01504074]		50 participants (Actual)	Observational	2011-11-30	Completed
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee [NCT01487161]	Phase 2	229 participants (Actual)	Interventional	2012-06-30	Completed
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy. [NCT01666236]	Phase 4	0 participants (Actual)	Interventional	2012-09-30	Withdrawn(stopped due to Lack of resources)
Changes Noted After Suprachoroidal Triamcinolone Acetonide Injection. [NCT05288192]		30 participants (Anticipated)	Interventional	2022-02-15	Recruiting
Bayesian Non-inferiority Trial of Injection Therapies for Acromioclavicular Joint Pain: a Randomized Clinical Trial [NCT05161468]	Phase 4	150 participants (Anticipated)	Interventional	2022-07-01	Recruiting
An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT02381652]	Phase 3	242 participants (Actual)	Interventional	2015-02-28	Completed
Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata [NCT01797432]	Phase 2	14 participants (Actual)	Interventional	2009-03-31	Completed
Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL) [NCT00815360]	Phase 2	22 participants (Actual)	Interventional	2008-02-29	Completed
Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment [NCT01703325]	Phase 4	16 participants (Actual)	Interventional	2010-11-30	Completed
An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses [NCT01736670]		30 participants (Actual)	Interventional	2012-04-30	Completed
Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis: a Randomized Controlled Superiority Trial [NCT06176248]		62 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. [NCT05106192]		22 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery [NCT01800708]		60 participants (Actual)	Interventional	2010-01-31	Completed
Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification [NCT01801774]	Phase 4	140 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial. [NCT04614311]	Phase 4	202 participants (Anticipated)	Interventional	2020-12-01	Recruiting
[NCT00370539]	Phase 3	0 participants	Interventional	2006-09-30	Recruiting
Effect of Intra-articular Steroids on Structural Progression of Knee OA: A Randomized Controlled Trial [NCT01230424]	Phase 4	140 participants (Actual)	Interventional	2011-03-31	Completed
Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis [NCT01789320]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2013-02-28	Completed
A Randomized, Double-Blind Study of the Efficacy of Steroid Supplementation After Temporomandibular Joint Arthrocentesis [NCT01770912]	Phase 2	24 participants (Actual)	Interventional	2013-03-31	Completed
A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee [NCT02468583]	Phase 2	6 participants (Actual)	Interventional	2015-02-28	Terminated
Randomized Prospective Study of Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Steroid Injection [NCT03166761]	Phase 4	41 participants (Actual)	Interventional	2017-09-14	Terminated(stopped due to recruitment and staffing)
A Double-blind Randomized Controlled Trial Comparing the Effects of Subacromial Injection With Corticosteroid Versus NSAID in Patients With Shoulder Impingement Syndrome [NCT01449448]		0 participants (Actual)	Interventional	2000-09-30	Withdrawn(stopped due to PI didn't have time to finish approval process)
Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury [NCT04331002]	Phase 2	1 participants (Actual)	Interventional	2020-08-21	Terminated(stopped due to Funding Termination)
Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial [NCT04361513]	Phase 4	64 participants (Actual)	Interventional	2020-04-15	Completed
Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial [NCT03127137]	Phase 4	123 participants (Actual)	Interventional	2018-08-01	Completed
A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (T [NCT03378076]	Phase 2	24 participants (Actual)	Interventional	2017-12-06	Completed
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) [NCT03380026]	Phase 2	28 participants (Actual)	Interventional	2017-12-13	Completed
Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study [NCT03797872]	Phase 4	1 participants (Actual)	Interventional	2019-04-17	Completed
An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD [NCT01175395]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2010-09-30	Completed
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases: A Pilot Study [NCT05488860]		20 participants (Anticipated)	Interventional	2022-07-30	Recruiting
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal [NCT02317276]	Phase 4	11 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Unable to meet the study's recruitment goals)
SporTRIA Study: A Multicentre Trial for Excretion Kinetics of Triamcinolone Acetonide Following Sport Related Intra-articular Injections in Knees; Definitions of the Washout Periods [NCT04574232]		20 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee. [NCT03086759]	Phase 4	99 participants (Actual)	Interventional	2017-01-02	Completed
Comparison of the Effects of Ultrasonography-guided Suprascapular Nerve Block and Intra-articular Shoulder Injection on Pain, Functional Status and Range of Motion in Patients With Adhesive Capsulitis; Randomized, Controlled Trial [NCT05909462]		60 participants (Actual)	Interventional	2023-01-21	Completed
Steroid and Sodium Hyaluronate Hydrodilatation [NCT05861570]		84 participants (Anticipated)	Interventional	2023-05-18	Recruiting
A Prospective Triple-Blinded Single-Center Study of Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid Treatment for Keloids [NCT04786210]	Phase 4	20 participants (Actual)	Interventional	2021-01-30	Completed
Modified SALT Score for Assessment of Alopecia Areata [NCT04412148]	Phase 4	20 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus [NCT02453503]	Phase 2	60 participants (Actual)	Interventional	2014-01-31	Completed
Efficacy of Autologous Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids [NCT04391621]	Phase 2	30 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Subakromiyal sıkışma Sendromunda Hyaluronik Asit, Kortikosteroid ve Elektroterapi [NCT04833738]		90 participants (Actual)	Interventional	2013-09-11	Completed
Thoracic Epidural Morphine Versus Triamcinolone Acetonide Analgesia in Flail Chest [NCT03413059]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2018-02-01	Not yet recruiting
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema [NCT00105027]	Phase 3	682 participants (Actual)	Interventional	2004-10-31	Completed
Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis [NCT01830699]		33 participants (Actual)	Interventional	2013-03-31	Completed
The Effectiveness of Intra-articular Corticosteroid Injection in Patients With Whiplash-related Neck Pain [NCT04959721]		32 participants (Anticipated)	Interventional	2021-07-15	Not yet recruiting
Effects of Ultrasound-guide Hypertonic Dextrose Injection for Chronic Subacromial Bursitis [NCT04916353]		60 participants (Anticipated)	Interventional	2021-06-10	Recruiting
[NCT00373282]	Phase 3	0 participants	Interventional	2001-06-30	Completed
Comparing Low Dose and High Dose Steroid Injection for Adhesive Capsulitis [NCT04364425]		80 participants (Anticipated)	Interventional	2020-05-04	Recruiting
Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis [NCT03871465]		111 participants (Actual)	Interventional	2018-08-01	Completed
A Randomized, Double-blind, Active-control, Multicenter, Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra Compared to Intramuscular Triamcinolone in the Treatment of Acute Gouty Arthritis, Followed by an Extension Period of up to 2 Year [NCT03002974]	Phase 2	165 participants (Actual)	Interventional	2016-12-31	Completed
Cell Therapy for Patients With Symptomatic Knee Osteoarthritis: Phase I / II, Controlled, Randomized and Double-blind Clinical Trial [NCT04863183]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial [NCT03634852]	Phase 4	1,000 participants (Actual)	Interventional	2016-10-01	Completed
A Clinical and Immunological Study of Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata: A Randomized Controlled Clinical Trial [NCT01559584]		40 participants (Actual)	Interventional	2012-03-31	Completed
Outcome in Shoulder Capsulitis (Frozen Shoulder) Between Corticosteroid and Corticosteroid With Distension Compared to Wait and See Policy, a Randomised Controlled Trial [NCT01570985]	Phase 3	120 participants (Anticipated)	Interventional	2010-02-28	Active, not recruiting
Randomized Multicenter Clinical Trial of Three Parallel Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macu [NCT01572350]	Phase 3	105 participants (Anticipated)	Interventional	2010-10-31	Completed
[NCT01599273]	Phase 4	50 participants (Actual)	Interventional	2012-05-31	Completed
Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions [NCT05345808]		46 participants (Actual)	Interventional	2021-03-01	Completed
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection [NCT02084706]		60 participants (Actual)	Interventional	2014-03-31	Completed
[NCT00370370]	Phase 3	0 participants	Interventional	2005-11-30	Active, not recruiting
[NCT00370669]	Phase 3	150 participants	Interventional	2005-11-30	Recruiting
Safety and Effectiveness of Single-dose Subconjunctival Triamcinolone Compared to Topical Prednisolone Eye Drops in Manual Small Incision Cataract Surgery [NCT05248139]		100 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Treatment of Early Nasal Polyposis With Topical Triamcinolone [NCT01222871]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to not enough particpants)
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee [NCT02357459]	Phase 3	486 participants (Actual)	Interventional	2015-01-31	Completed
Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery [NCT00238563]		0 participants (Actual)	Interventional		Withdrawn(stopped due to Funding not secured)
The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections [NCT02592629]	Phase 4	19 participants (Actual)	Interventional	2016-02-01	Terminated(stopped due to Lack of time to enroll due to additional responsibilities of the PI and research coordinator.)
Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis [NCT02680301]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
[NCT00369863]	Phase 2	76 participants	Interventional	2002-06-30	Completed
[NCT00371111]	Phase 1	40 participants (Anticipated)	Interventional	2006-08-31	Active, not recruiting
The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation [NCT02877485]	Phase 4	42 participants (Actual)	Interventional	2016-08-31	Completed
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis: A Randomized, Controlled Trial [NCT05992883]	Phase 3	240 participants (Anticipated)	Interventional	2023-07-28	Recruiting
Comparison of the Efficacy of Two Techniques for Sacroiliac Joint Injection: Ultrasound Guidance Versus Fluoroscopic Guidance [NCT02420041]		28 participants (Actual)	Interventional	2012-10-31	Completed
Peripheral Nerve Injections for the Treatment of Upper Extremity Complex Regional Pain Syndrome: A Feasibility Study for a Proposed Randomized Design [NCT04744675]	Phase 4	50 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
A Prospective, Randomized Controlled Trial on the Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF) [NCT02577991]		80 participants (Actual)	Interventional	2014-02-28	Completed
The Soft Tissue Injection of Corticosteroid And Local Anaesthetic Study - A Single Site, Non-inferiority Randomised Control Trial Evaluating Pain After Soft Tissue Corticosteroid Injections With and Without Local Anaesthetic [NCT04253457]	Phase 3	100 participants (Anticipated)	Interventional	2020-02-26	Recruiting
Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome [NCT03463915]	Phase 3	90 participants (Actual)	Interventional	2019-01-25	Completed
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis [NCT04036188]	Early Phase 1	24 participants (Anticipated)	Interventional	2019-10-16	Recruiting
Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy [NCT02379000]	Phase 4	50 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
A Stratified Investigation of a Single Injection of ZILRETTA™ (Triamcinolone Acetonide Extended-release Injectable Suspension) for Symptomatic Relief in Patients With Idiopathic Adhesive Capsulitis of the Shoulder [NCT04831255]	Phase 1	50 participants (Anticipated)	Interventional	2019-06-21	Recruiting
Is the Efficacy of Epidural Steroid Injections Related to the Different Volume Injections? :A Randomised, Clinical Trial [NCT02343432]		75 participants (Actual)	Interventional	2008-03-31	Completed
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective [NCT01470989]	Phase 3	136 participants (Actual)	Interventional	2011-11-30	Completed
Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome; a Comparative Study [NCT04434105]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2020-02-01	Active, not recruiting
A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Ad [NCT03317015]	Phase 3	260 participants (Actual)	Interventional	2016-11-30	Completed
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial [NCT02447185]	Phase 3	200 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee (EEFFEK Study) [NCT03062787]		60 participants (Actual)	Interventional	2017-04-05	Completed
A Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus- Split-Mouth Randomised [NCT04976673]	Phase 2	30 participants (Actual)	Interventional	2020-12-10	Completed
A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects [NCT03758365]	Phase 1	36 participants (Actual)	Interventional	2018-11-05	Completed
Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial [NCT03237533]	Early Phase 1	32 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT03191903]	Phase 3	576 participants (Actual)	Interventional	2017-05-25	Completed
Triamcinolone Versus Methylprednisolone in Ultrasound Guided Transversus Abdominis Plane Block in Major Open Abdominal Surgery [NCT04480775]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2020-07-15	Completed
Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas [NCT04658836]	Phase 1	21 participants (Actual)	Interventional	2020-02-01	Completed
Using Intraoperative Triamcinolone Acetonide Irrigation to Reduce Post-Operative Pain From Scleral Buckle Surgery [NCT04701593]	Phase 4	24 participants (Anticipated)	Interventional	2020-01-03	Recruiting
Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance [NCT05058209]	Phase 4	20 participants (Actual)	Interventional	2020-11-30	Completed
Suprachoroidal Triamcinolone Acetonide Injection A Novel Therapy for Serous Retinal Detachment in Vogt-Koyanagi Harada's Disease [NCT05031143]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2020-04-01	Completed
Proof of Concept Investigation of the Steroid-reducing Effects of Crisaborole in Children [NCT03832010]	Phase 4	24 participants (Actual)	Interventional	2019-12-17	Active, not recruiting
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee [NCT02637323]	Phase 2	81 participants (Actual)	Interventional	2015-11-30	Completed
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. [NCT04994951]	Phase 2	200 participants (Anticipated)	Interventional	2021-09-30	Recruiting
Efficacy of Corticosteroid Injection Into Coracohumeral Ligament in Patients With Adhesive Capsulitis of the Shoulder [NCT03013205]		60 participants (Anticipated)	Interventional	2017-02-28	Not yet recruiting
Comparison of Ultrasound-guided Corticosteroid Injection Versus Corticosteroid Injection and Hydrodissection for Carpal Tunnel Syndrome [NCT04346030]		60 participants (Anticipated)	Interventional	2020-04-17	Recruiting
Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial [NCT01045694]	Phase 4	8 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Unable to acquire additional funding needed to continue this study.)
Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy [NCT01652495]	Phase 4	44 participants (Actual)	Interventional	2012-03-31	Completed
[NCT01614509]		45 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective [NCT01362608]	Phase 3	136 participants (Actual)	Interventional	2011-06-20	Terminated
A Phase 2, Randomized, Active and Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis [NCT04885972]	Phase 2	124 participants (Actual)	Interventional	2021-11-15	Active, not recruiting
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis [NCT03991936]	Phase 4	10 participants (Actual)	Interventional	2020-03-11	Completed
Mobile Device Based Telerehabilitation for Frozen Shoulder-A Prospective Randomized Controlled Study. [NCT05980572]		76 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata [NCT04147845]		60 participants (Actual)	Interventional	2019-10-30	Completed
Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone [NCT02242630]		61 participants (Actual)	Interventional	2014-09-30	Completed
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis [NCT06074315]		338 participants (Anticipated)	Interventional	2023-10-01	Recruiting
A Randomized, Triple-Blinded Study of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Bupivicaine and Triamcinolone vs. Bupivicaine Alone for the Treatment of Pain in Chronic Pancreatitis [NCT00658736]	Phase 3	40 participants (Actual)	Interventional	2008-03-31	Completed
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee [NCT02003365]	Phase 2	50 participants (Actual)	Interventional	2013-11-30	Completed
Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial [NCT05887804]	Phase 4	24 participants (Actual)	Interventional	2021-10-01	Completed
Prospective, Randomized Trial of Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection [NCT04498260]	Phase 4	30 participants (Anticipated)	Interventional	2019-01-21	Recruiting
The Long-term Effect of Perineural Injection Therapy Versus Steroid in Patients With Carpal Tunnel Syndrome [NCT02990962]		54 participants (Actual)	Interventional	2016-12-31	Completed
Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus [NCT02329600]	Phase 3	40 participants (Actual)	Interventional	2013-06-30	Completed
The Long-term Effect for Perineural Injection Therapy for Ulnar Neuropathy at Elbow [NCT02986906]		36 participants (Actual)	Interventional	2017-03-01	Completed
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma [NCT01748175]		715 participants (Actual)	Observational	2013-01-31	Completed
Effect of the Combination of Photobiomodulation Therapy and the Intralesional Administration of Corticoid in the Preoperative and Postoperative Periods of Keloid Surgery: a Randomized, Controlled, Double-blind Trial [NCT04824612]		58 participants (Anticipated)	Interventional	2021-08-30	Enrolling by invitation
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study [NCT04207931]	Phase 4	250 participants (Anticipated)	Interventional	2018-04-30	Recruiting
Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA) [NCT02310295]		45 participants (Actual)	Interventional	2009-01-31	Completed
Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized [NCT03382925]	Phase 4	16 participants (Actual)	Interventional	2017-12-20	Terminated(stopped due to Not enough cervical interlaminar patients who meet criteria in order to meet recruitment goals.)
The Clinical Application of PLT Combined With Steroid in Lateral Epicondylopathy and Supraspinatus Calcific Tendinopathy [NCT05648032]	Phase 3	180 participants (Anticipated)	Interventional	2022-10-06	Recruiting
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT04231318]	Phase 3	231 participants (Actual)	Interventional	2020-09-11	Completed
Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance [NCT04261049]	Phase 1	35 participants (Actual)	Interventional	2020-08-01	Completed
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery [NCT05158699]	Phase 3	808 participants (Anticipated)	Interventional	2021-10-13	Recruiting
Comparison of Corticosteroid and Repeated Dextrose Hydro-dissection for Carpal Tunnel Syndrome Patients [NCT04579783]		60 participants (Anticipated)	Interventional	2020-11-27	Recruiting
Evaluation of Triamcinolone's Efficacy on the Ultrasound- Guided Infiltration in the Quadratus Lumborum Syndrome: a Double Blind, Randomized, Controlled Study [NCT03407027]	Phase 4	66 participants (Anticipated)	Interventional	2017-11-01	Enrolling by invitation
Painful Inflammatory Carpometacarpal-1 Osteoarthritis Treated With Intraarticular Steroids, Saline or an Occupational Therapy Intervention: the PICASSO Trial. [NCT06084364]	Phase 4	354 participants (Anticipated)	Interventional	2023-11-03	Recruiting
Pilot Study of Early Postoperative Fractional Ablative Laser Treatment of Skin Grafts for Burns [NCT04176705]		9 participants (Actual)	Interventional	2020-12-14	Completed
Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis: A Randomized Placebo-Controlled Clinical Trial [NCT00746889]		79 participants (Actual)	Interventional	2004-03-31	Completed
A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee [NCT01487200]	Phase 2	24 participants (Actual)	Interventional	2012-07-31	Completed
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering [NCT05535738]	Phase 2/Phase 3	45 participants (Anticipated)	Interventional	2022-11-15	Recruiting
Predictability of the Effects of Facet Joint Infiltration in the Degenerate Lumbar Spine When Assessing MRI Scans [NCT03308149]		50 participants (Actual)	Observational	2016-01-10	Completed
Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo [NCT03365141]		12 participants (Anticipated)	Interventional	2017-11-14	Recruiting
A Short Term Outcomes of Subacromial Injection of Combined Corticosteroid With Low Volume Compared to High Volume of Local Anesthetic for Rotator Cuff Impingement Syndrome: A Randomized Controlled Trials [NCT03120923]	Phase 4	52 participants (Actual)	Interventional	2015-01-01	Completed
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered With the Oxulumis® Ophthalmic Administration Device i [NCT05512962]	Phase 2	20 participants (Actual)	Interventional	2022-08-31	Active, not recruiting
Triamcinolone Levels in Cochlear Perilymph [NCT03248856]	Phase 1	40 participants (Actual)	Interventional	2017-10-02	Completed
A Double-Blind, Randomized Study to Compare Onabotulinumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain [NCT02369068]		21 participants (Actual)	Interventional	2015-08-31	Completed
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial [NCT02374060]	Phase 3	192 participants (Actual)	Interventional	2015-06-16	Completed
Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis [NCT03200886]		100 participants (Actual)	Observational	2017-05-24	Active, not recruiting
Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial [NCT03293368]	Phase 2	20 participants (Actual)	Interventional	2018-01-01	Completed
A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata [NCT01898806]	Phase 4	11 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to The PI left the Columbia University Medical Center. Study was not Completed.)
A Prospective Randomized Controlled Trial of Standardized C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for the Treatment of Cervical Radicular Pain [NCT02095197]	Phase 4	79 participants (Actual)	Interventional	2014-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00105027 (4) [back to overview]	Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography
NCT00105027 (4) [back to overview]	The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit
NCT00105027 (4) [back to overview]	Adverse Ocular Outcomes
NCT00105027 (4) [back to overview]	Changes From Baseline in Best-corrected ETDRS Visual Acuity Score
NCT00203294 (1) [back to overview]	Headache Severity as Measured on an 11-point Verbal Scale (0 to 10):0=No Pain 10=Excruciating Pain
NCT00242580 (6) [back to overview]	Mean Change From Baseline in Total Area of Lesion at 12 Months
NCT00242580 (6) [back to overview]	Number of Participants Requiring Verteporfin Treatment Throughout the Study
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12
NCT00242580 (6) [back to overview]	Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Popping Sensation in Ears
NCT00279916 (8) [back to overview]	Per-Ear Treatment Outcome
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Plugged Sensation in Ears
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Fullness or Pressure in Ears
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Dampened Hearing/Loss Worse Than Usual
NCT00279916 (8) [back to overview]	Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment
NCT00279916 (8) [back to overview]	Complete Normalization of Abnormal Tympanometry Considering the Subjects Who Took Additional Treatment as Having Incomplete Resolution
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Pain in Ears
NCT00367133 (14) [back to overview]	Central Subfield Thickness at 2 Years
NCT00367133 (14) [back to overview]	Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years
NCT00367133 (14) [back to overview]	Change in Central Subfield Thickness on OCT Baseline to 3 Years
NCT00367133 (14) [back to overview]	Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.
NCT00367133 (14) [back to overview]	Change in Visual Acuity From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Change in Visual Acuity From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Mean Change in Central Subfield Thickness Baseline to 2 Years
NCT00367133 (14) [back to overview]	Median Change in Central Subfield Thickness Baseline to 2 Years
NCT00367133 (14) [back to overview]	Median Change in Visual Acuity Baseline to 2 Years
NCT00367133 (14) [back to overview]	Overall Central Subfield Thickening Decreased by >=50% Baseline to 2 Years
NCT00367133 (14) [back to overview]	Percentage of Eyes With a Change in Central Subfield Thickness on OCT <250 Microns From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Distribution of Change in Visual Acuity Baseline to 2 Years
NCT00367133 (14) [back to overview]	Distribution of Visual Acuity Change Baseline to 3 Years
NCT00367133 (14) [back to overview]	Central Subfield Thickness < 250 Microns at 2 Years
NCT00369486 (6) [back to overview]	Mean Visual Acuity Letter Score at Each Follow-up Visit
NCT00369486 (6) [back to overview]	Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks
NCT00369486 (6) [back to overview]	Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Change in Visual Acuity Letter Score From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Change in Central Subfield Thickening From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Central Subfield Thickness <250 Microns From Baseline Through 34 Weeks
NCT00398866 (2) [back to overview]	Pain Visual Analogue Scale (VAS)
NCT00398866 (2) [back to overview]	Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire
NCT00444600 (21) [back to overview]	Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline
NCT00444600 (21) [back to overview]	Number of Injections in First Year
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema
NCT00444600 (21) [back to overview]	Change From Severe Non-proliferative Diabetic Retinopathy or Worse From Baseline to 1-year
NCT00444600 (21) [back to overview]	Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year
NCT00444600 (21) [back to overview]	Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
NCT00444600 (21) [back to overview]	Percentage of Eyes Receiving Laser at the 48 Week Visit (%)
NCT00444600 (21) [back to overview]	Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity
NCT00444600 (21) [back to overview]	Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Central Subfield Thickness < 250 With at Least a 25 Micron Decrease From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Mean Optical Coherence Tomography Retinal Volume at 1 Year
NCT00444600 (21) [back to overview]	Number of Laser Treatments Received Prior to the 1 Year Visit
NCT00444600 (21) [back to overview]	Major Ocular Adverse Events During First Year of Follow-Up
NCT00444600 (21) [back to overview]	Eyes With Alternative Treatments Prior to the 1-year Visit
NCT00444600 (21) [back to overview]	Distribution of Logarithmic Transformation of Optical Coherence Tomography (LogOCT) Improvement and Worsening
NCT00445003 (8) [back to overview]	Total Optical Coherence Tomography Retinal Volume
NCT00445003 (8) [back to overview]	Eyes With Anti-vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Number of Eyes With Additional Number of Treatments for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Additional Treatments for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks
NCT00445003 (8) [back to overview]	Change in Optical Coherence Tomography Central Subfield Thickness
NCT00445003 (8) [back to overview]	Change in Optical Coherence Tomography Retinal Volume
NCT00445003 (8) [back to overview]	Change in Visual Acuity From Baseline
NCT00473083 (7) [back to overview]	Duration of Treatment
NCT00473083 (7) [back to overview]	Time to First Presentation of Rash
NCT00473083 (7) [back to overview]	Severity of Rash Caused by Erlotinib
NCT00473083 (7) [back to overview]	Time Duration From Onset of Rash Until Resolution
NCT00473083 (7) [back to overview]	Overall Incidence of Grade 3 Rash
NCT00473083 (7) [back to overview]	Overall Incidence of Rash
NCT00473083 (7) [back to overview]	Overall Survival
NCT00484679 (1) [back to overview]	Mean Change in Cortisol Levels From Baseline to Week 24
NCT00588354 (8) [back to overview]	Pain Score at 2 Weeks as Measured by the Multidimensional Pain Inventory (MPI)
NCT00588354 (8) [back to overview]	Pain Score at 4 Weeks as Measured by the Multidimensional Pain Inventory (MPI)
NCT00588354 (8) [back to overview]	Pain Disability Score at 2 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire (ODI)
NCT00588354 (8) [back to overview]	Pain Intensity Score at 4 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)
NCT00588354 (8) [back to overview]	Pain Intensity Score at 2 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)
NCT00588354 (8) [back to overview]	Pain Disability Score at 4 Weeks as Measured by the Roland-Morris Disability Questionnaire
NCT00588354 (8) [back to overview]	Pain Disability Score at 4 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire
NCT00588354 (8) [back to overview]	Pain Disability Score at 2 Weeks as Measured by the Roland-Morris Disability Questionnaire
NCT00597766 (4) [back to overview]	Pain Free Abduction Range of Motion (ROM)
NCT00597766 (4) [back to overview]	Pain Free External Rotation Range of Motion (ROM)
NCT00597766 (4) [back to overview]	BPI 12 (Brief Pain Inventory, Question 12) Pain Questionnaire
NCT00597766 (4) [back to overview]	Fugl-Meyer Motor Assessment, Upper Limb Domain
NCT00623766 (9) [back to overview]	Overall Survival (OS)
NCT00623766 (9) [back to overview]	Best Overall Response Rate (BORR) by Modified World Health Organization (mWHO) Criteria and by Immune-relate Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Disease Control Rate by Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria
NCT00623766 (9) [back to overview]	Duration of Response (DOR) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Number of Participants Surviving at 6, 12, 18, 24, and 36 Months (Overall Survival [OS] Rate)
NCT00623766 (9) [back to overview]	Number of Participants Who Died or Had a Treatment-related Adverse Event (AE), Immune-related AE, Immune-related Serious Adverse Event (SAE), Nervous System Disorder, Treatment-related Nervous System Disorder, SAE, and AE Leading to Discontinuation
NCT00623766 (9) [back to overview]	Onset of Response by Modified World Health Organization (mWHO) Criteria and Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Progression-free Survival (PFS) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)
NCT00658736 (2) [back to overview]	Change in Pain Disability Index
NCT00658736 (2) [back to overview]	Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component
NCT00682539 (2) [back to overview]	Efficacy of the Treatment Assessed by Standard Optical Coherence Tomography (OCT)
NCT00682539 (2) [back to overview]	Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts.
NCT00746889 (2) [back to overview]	Change in WOMAC Pain Subscale
NCT00746889 (2) [back to overview]	Change in Western Ontario and McMasters Universities Arthritis Index (WOMAC) Pain Subscale
NCT00798369 (7) [back to overview]	Serum Amyloid Protein (SAA) Levels at 72 Hours, 7days, 4 Weeks and 8 Weeks Post Dose for Each Treatment Group
NCT00798369 (7) [back to overview]	The Change in Pain Intensity in the Target Joint Following Canakinumab Administration Compared to Triamcinolone Acetonide
NCT00798369 (7) [back to overview]	Percentage of Participants With an Excellent or Good Response With Regards to the Patient's Global Assessment of Response to Treatment
NCT00798369 (7) [back to overview]	The Time to 50% Reduction of Baseline Pain Intensity in the Target Joint
NCT00798369 (7) [back to overview]	The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a 0-100 mm Visual Analog Scale (VAS)
NCT00798369 (7) [back to overview]	Amount of Rescue Medication Taken for Each Treatment Group
NCT00798369 (7) [back to overview]	High Sensitivity C-reactive Protein (hsCRP) at 72 Hours, 7days, 4 Weeks and 8 Weeks Post Dose for Each Treatment Group
NCT00815360 (2) [back to overview]	Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months
NCT00815360 (2) [back to overview]	Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale (Visual Analog Scale).
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale (Visual Analog Scale).
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a Visual Analog Scale (VAS Scale)
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Treatment Success - Event Rates in Each Group
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on a 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00853905 (5) [back to overview]	Intraocular Pressure (IOP)
NCT00853905 (5) [back to overview]	Bleb Appearance
NCT00853905 (5) [back to overview]	Anterior Chamber Inflammation (Flare)
NCT00853905 (5) [back to overview]	Patient Comfort
NCT00853905 (5) [back to overview]	Ocular Hypotensive Medications
NCT00924508 (2) [back to overview]	Change in Disease Severity: Percent Change in Mean EASI Score
NCT00924508 (2) [back to overview]	Number of Adverse Events Associated With Treatment
NCT01029652 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)
NCT01029652 (33) [back to overview]	SF36 Physical Function Score at Week 12
NCT01029652 (33) [back to overview]	Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)
NCT01029652 (33) [back to overview]	Time to Complete Resolution of Pain
NCT01029652 (33) [back to overview]	Time to First Intake of Rescue Medication After the Last Post Baseline Flare.
NCT01029652 (33) [back to overview]	Time to First New Flare
NCT01029652 (33) [back to overview]	Time to First New Flare
NCT01029652 (33) [back to overview]	Time to First New Flare: Survival Analysis by Treatment (72 Weeks Overall)
NCT01029652 (33) [back to overview]	Amount of Rescue Medication Taken
NCT01029652 (33) [back to overview]	Physician's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) Levels for Patients Re-treated With or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (24 Weeks Overall)
NCT01029652 (33) [back to overview]	Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (72 Weeks Overall)
NCT01029652 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels for Core and 24 Weeks Overall
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale)
NCT01029652 (33) [back to overview]	Patient's Global Assessment of Response to Treatment
NCT01029652 (33) [back to overview]	Patient's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Percentage of Participants Who Took Rescue Medication
NCT01029652 (33) [back to overview]	Flare Rate Per Year
NCT01029652 (33) [back to overview]	Physician's Assessment of Erythema for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Joint Swelling for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Joint Tenderness for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01029652 (33) [back to overview]	Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint
NCT01029652 (33) [back to overview]	Physician's Global Assessment of Response to Treatment
NCT01029652 (33) [back to overview]	Mean Number of New Gout Flares Per Patient
NCT01029652 (33) [back to overview]	Serum Amyloid A Protein (SAA) Levels for Patients Re-treated With or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Percentage of Participants With Maximum Severity of Last Post-baseline Flare (5-point Likert Scale)
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint on a Visual Analog Scale (VAS) in Extension
NCT01029652 (33) [back to overview]	Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks
NCT01029652 (33) [back to overview]	Mean Number of New Gout Flares Per Patient During the 24 Weeks of the Study
NCT01029652 (33) [back to overview]	Percentage of Participants With Complete Resolution of Pain
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Currently Most-affected Joint (Likert Scale)
NCT01080131 (33) [back to overview]	Time to First New Flare: Survival Analysis During the 12 Weeks of Study
NCT01080131 (33) [back to overview]	Time to First New Flare: Survival Analysis by Treatment Over 72 Weeks
NCT01080131 (33) [back to overview]	Time to Complete Resolution of Pain; Survival Analysis
NCT01080131 (33) [back to overview]	Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS)
NCT01080131 (33) [back to overview]	SF 36 Physical Function Score at Week 12
NCT01080131 (33) [back to overview]	Physician's Assessment of Joint Tenderness for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Physician's Assessment of Joint Swelling for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Physician's Assessment of Erythema for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Percentage of Patients With Maximum Severity of New Gout Flares as Severe or Extreme
NCT01080131 (33) [back to overview]	Percentage of Participants Who Took Rescue Medication
NCT01080131 (33) [back to overview]	Patient's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint
NCT01080131 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Number of Participants With Adverse Events, Death and Serious Adverse Events During 24 Weeks
NCT01080131 (33) [back to overview]	Time to First Intake of Rescue Medication
NCT01080131 (33) [back to overview]	Serum Amyloid A Protein (SAA) Levels for Participants Re-treated With or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Last Post-Baseline Measured on a Visual Analog Scale (VAS)
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100 mm VAS)
NCT01080131 (33) [back to overview]	Physician's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS) at 72 Hours Post-dose
NCT01080131 (33) [back to overview]	Pharmacokinetic Concentrations
NCT01080131 (33) [back to overview]	Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks of the Study
NCT01080131 (33) [back to overview]	Mean Number of New Gout Flares Per Patient During 24 Weeks
NCT01080131 (33) [back to overview]	Flare Rate Per Year
NCT01080131 (33) [back to overview]	Patient's Global Assessment of Response to Treatment
NCT01080131 (33) [back to overview]	Physician's Global Assessment of Response to Treatment
NCT01080131 (33) [back to overview]	Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint
NCT01080131 (33) [back to overview]	Number of Participants With Adverse Events, Death and Serious Adverse Events (72 Weeks Overall)
NCT01080131 (33) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01080131 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) Levels for Participants Re-treated With or Switched to Canakinumab
NCT01080131 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels
NCT01080131 (33) [back to overview]	Amount of Rescue Medication Taken
NCT01080131 (33) [back to overview]	Time to the First New Gout Flare During 24 Weeks
NCT01154153 (6) [back to overview]	Ratio of Serum Cortisol Area Under Curve [AUC(0-24 hr)] at the End of Treatment to Baseline
NCT01154153 (6) [back to overview]	Number of Participants Using Rescue Medication
NCT01154153 (6) [back to overview]	Number of Participants by Relief Level as Evaluated by the Physician
NCT01154153 (6) [back to overview]	Number of Participants by Relief Level as Evaluated by the Participant
NCT01154153 (6) [back to overview]	The Percent of Days of Rescue Medication Use During the Double-blind Treatment Phase
NCT01154153 (6) [back to overview]	Change From Baseline in the Reflective Total Nasal Symptom Score (rTNSS)
NCT01175395 (2) [back to overview]	To Assess the Safety & Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD
NCT01175395 (2) [back to overview]	To Determine the Number of Retreatments With Lucentis in Eyes Initially Treated With 20089 TA and Lucentis
NCT01230424 (11) [back to overview]	Change in Volume of Peri-articular Bone Marrow Lesions Measured on Knee MRI.
NCT01230424 (11) [back to overview]	Change in Time to Complete a Twenty-meter Walk.
NCT01230424 (11) [back to overview]	Change in Volumetric Cartilage Damage Index (CDI) Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
NCT01230424 (11) [back to overview]	Change in Patient's Global Assessment (Visual Analogue Scale).
NCT01230424 (11) [back to overview]	Change in Time to Complete 5 Chair Stands.
NCT01230424 (11) [back to overview]	Change in Mean Cartilage Thickness in the Index Compartment (Compartment With the Most Damage)
NCT01230424 (11) [back to overview]	Change in Knee Stiffness During the Past 48 Hours From the WOMAC LK3.1 Stiffness Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Knee Pain Severity During the Past 48 Hours From the WOMAC LK3.1 Pain Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Function Severity During the Past 48 Hours From the WOMAC LK3.1 Function Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Effusion Volume Measured on Knee MRI.
NCT01230424 (11) [back to overview]	Change in Area of Denudation Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
NCT01356602 (18) [back to overview]	Patient's Assessment of Pain Intensity on a 0-100mm VAS
NCT01356602 (18) [back to overview]	Physician's Global Assessment of Response to Treatment on a 5 Point Likert Scale
NCT01356602 (18) [back to overview]	Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups
NCT01356602 (18) [back to overview]	Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups
NCT01356602 (18) [back to overview]	Number of Patients With at Least One New Gouty Arthritis Flare After Baseline
NCT01356602 (18) [back to overview]	Patient's Assessment of Pain Intensity on a 5-point Likert Scale
NCT01356602 (18) [back to overview]	Amount of Rescue Medication Taken (mg)
NCT01356602 (18) [back to overview]	Physician's Assessment of Swelling
NCT01356602 (18) [back to overview]	Physician's Assessment of Tenderness
NCT01356602 (18) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01356602 (18) [back to overview]	Time to the First New Gouty Arthritis Flare
NCT01356602 (18) [back to overview]	Time to Resolution of Gouty Arthritis Flare as Reported by Patient
NCT01356602 (18) [back to overview]	C-reactive Protein Level
NCT01356602 (18) [back to overview]	Patient's Global Assessment of Response to Treatment on a 5-point Likert Scale
NCT01356602 (18) [back to overview]	Physician's Assessment of Erythema
NCT01356602 (18) [back to overview]	Time to First Rescue Medication Intake
NCT01356602 (18) [back to overview]	Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS
NCT01356602 (18) [back to overview]	Proportion of Patients With Rescue Medication Intake
NCT01362608 (16) [back to overview]	Time to First Rescue Medication Intake
NCT01362608 (16) [back to overview]	Physician's Assessment of Range of Motion: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Physician's Assessment of Swelling: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Time to First New Flare: Survival Analysis by Treatment: Kaplan Meier Analysis
NCT01362608 (16) [back to overview]	The Number of Patients With at Least 1 New Gout Flare
NCT01362608 (16) [back to overview]	Patients Assessment of Gout Pain Intensity in the Most Effected Joint (0-100mm VAS): Summary Statistics by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Patient's Global Assessment of Response to Treatment: Frequency Table by Timepoint and Treatment Using a Likert Scale.
NCT01362608 (16) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale): Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Percent Patients Who Took Rescue Medication
NCT01362608 (16) [back to overview]	Physician's Assessment of Erythema: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Amount of Rescue Medication Taken at Baseline Flare and Post Baseline Flare.
NCT01362608 (16) [back to overview]	Time to Complete Resolution of Pain: Survival Analysis by Treatment
NCT01362608 (16) [back to overview]	Time to at Least a 50% Reduction in Baseline Pain Intensity: Survival Analysis by Treatment
NCT01362608 (16) [back to overview]	The Change in the Gout Pain Intensity in the Target Joint Following ACZ885 Administration Measured by Visual Analog Scale (VAS)
NCT01362608 (16) [back to overview]	High Sensitivity C-reactive Protein [hsCRP] Measured in the Serum at 72 Hours Post Dose
NCT01362608 (16) [back to overview]	Physician's Assessment of Tenderness: Frequency Table by Timepoint and Treatment
NCT01470989 (3) [back to overview]	Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants
NCT01470989 (3) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint
NCT01470989 (3) [back to overview]	Number of New Flares Per Participant
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	WOMAC A (Pain Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC B (Stiffness Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC C (Function Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.
NCT01487161 (16) [back to overview]	Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.
NCT01487161 (16) [back to overview]	Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Clinical Global Impression of Change Scores at Week 8
NCT01487161 (16) [back to overview]	Patient Global Impression of Change Scores at Week 8
NCT01487161 (16) [back to overview]	Percent of Responders According to OMERACT-OARSI Criteria at Week 8
NCT01487200 (5) [back to overview]	Change From Baseline in 24-hour Urinary Free Cortisol Excretion
NCT01487200 (5) [back to overview]	Change From Baseline in 24-hour Weighted Mean Serum Cortisol
NCT01487200 (5) [back to overview]	Change From Baseline to Each Measured Time Point Post-dose in Morning Serum Cortisol
NCT01487200 (5) [back to overview]	Characterize the Pharmacokinetic Profile of FX006 and TCA IR
NCT01487200 (5) [back to overview]	Total 24-hour Urinary Free Cortisol Excretion
NCT01614509 (2) [back to overview]	Changes of Central Retinal Thickness
NCT01614509 (2) [back to overview]	Additional Intravitreal Bevacizumab Injection
NCT01652495 (3) [back to overview]	Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis
NCT01652495 (3) [back to overview]	Functional Improvement Measured According to Percentage Change in Constant Score
NCT01652495 (3) [back to overview]	Reduction of Pain Severity Expressed as Percentage Change in VAS Score
NCT01670539 (8) [back to overview]	Changes in Telemonitor Symptoms Recorded From Baseline: Functioning
NCT01670539 (8) [back to overview]	Changes in Telemonitor Symptoms Recorded From Baseline: Dyspnea
NCT01670539 (8) [back to overview]	Changes in Telemonitor Data From Baseline: Weight
NCT01670539 (8) [back to overview]	Changes in Telemonitor Data From Baseline: Blood Pressure
NCT01670539 (8) [back to overview]	Changes in Telemonitor Data From Baseline: Temperature
NCT01670539 (8) [back to overview]	Changes in Telemonitor Data From Baseline: SpO2
NCT01670539 (8) [back to overview]	Changes in Telemonitor Data From Baseline: Pulse Rate
NCT01670539 (8) [back to overview]	Changes in Telemonitor Symptoms Recorded From Baseline: Pain
NCT01692756 (13) [back to overview]	Participant Pain Assessment
NCT01692756 (13) [back to overview]	Synovial C-terminal Peptide II (CTXII) Concentration
NCT01692756 (13) [back to overview]	Synovial Cartilage Oligomeric Matrix Protein (COMP) Concentration
NCT01692756 (13) [back to overview]	Efficacy of Kenalog to Alleviate Knee Pain
NCT01692756 (13) [back to overview]	Synovial Glycosaminoglycans (GAG) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1 Receptor Antagonist (IL-1ra) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1α (IL-1α) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1β (IL-1β) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 1 (MMP-1) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 3 (MMP-3) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 9 (MMP-9) Concentration
NCT01692756 (13) [back to overview]	Synovial TNF-stimulated Gene 6 Protein (TSG-6) Concentration
NCT01692756 (13) [back to overview]	Synovial Type I Collagen Cross-Linked N-Telopeptide (NTX-I) Concentration
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 12 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 6 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 2 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Motion at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Motion Without Pain at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Pain-Free Motion at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 12 Weeks
NCT01789320 (4) [back to overview]	Change in Intraocular Pressure (IOP)
NCT01789320 (4) [back to overview]	Central Subfield Thickness Using Optical Coherence Tomography (OCT)
NCT01789320 (4) [back to overview]	Vitreous Haze Grade
NCT01789320 (4) [back to overview]	Best Corrected Visual Acuity
NCT01797432 (2) [back to overview]	Number of Adverse Events Reported by Subjects
NCT01797432 (2) [back to overview]	Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline
NCT01830699 (3) [back to overview]	Number of Participants With Adverse Events as a Measure of Safety and Tolerability
NCT01830699 (3) [back to overview]	Improvement in Shoulder Function
NCT01830699 (3) [back to overview]	Improvement in Pain
NCT01898806 (1) [back to overview]	Number of Adverse Events
NCT01995045 (4) [back to overview]	Mean Acetaminophen Intake
NCT01995045 (4) [back to overview]	Mean Hydrocodone Intake
NCT01995045 (4) [back to overview]	Mean Oxycodone Intake
NCT01995045 (4) [back to overview]	Mean Pain Score
NCT02003365 (2) [back to overview]	Plasma Drug Concentrations by Time
NCT02003365 (2) [back to overview]	Concentration of Triamcinolone Acetonide in Synovial Fluid
NCT02084706 (1) [back to overview]	Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection
NCT02095197 (4) [back to overview]	Percentage of Participants With ≥50% Pain Reduction on the Numeric Rating Score (NRS) for Pain
NCT02095197 (4) [back to overview]	Decrease of > 6.8 Point Reduction in Medication Quntification Scale (MQS-III)
NCT02095197 (4) [back to overview]	Greater Than or Equal to a 30% Reduction in Oswestry Neck Disability Index Score
NCT02095197 (4) [back to overview]	Patient Global Impression of Change Score (PGIC) Less Than 3
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02120261 (4) [back to overview]	Duration of Pain Relief
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02242630 (2) [back to overview]	Change in Subject Reported Shoulder Pain as Measured by the Visual Analogue Scale
NCT02242630 (2) [back to overview]	Change in Shoulder Function, as Measured by the QuickDASH ®
NCT02329600 (2) [back to overview]	Salivary Total Oxidative Capacity
NCT02329600 (2) [back to overview]	Pain
NCT02357459 (14) [back to overview]	Responder Status as Defined by Proportion of Patients Experiencing >50% Decrease in Pain From Baseline in Weekly Mean of the ADP Scores at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Responder Status as Defined by Proportion of Patients Experiencing >30% Decrease in Pain From Baseline in Weekly Mean of the ADP Scores at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Subscale at Weeks 4, 8, 12 and 24
NCT02357459 (14) [back to overview]	Average Weekly and Total Consumption of Rescue Medications at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC A (Pain Subscale) at Weeks 4, 8, 12, 16, 20 and 24.
NCT02357459 (14) [back to overview]	Time to Onset of Pain Relief
NCT02357459 (14) [back to overview]	Area Under the Effect Curve (AUE) of Change From Baseline in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to Placebo
NCT02357459 (14) [back to overview]	AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
NCT02357459 (14) [back to overview]	AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 24 for FX006 Relative to Placebo
NCT02357459 (14) [back to overview]	Change From Baseline to Week 12 in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
NCT02357459 (14) [back to overview]	Change From Baseline to Each Week in Weekly Mean of the ADP Scores
NCT02357459 (14) [back to overview]	Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC C (Function Subscale) at Weeks 4, 8, 12, 16, 20 and 24
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC B (Stiffness Subscale) at Weeks 4, 8, 12, 16, 20 and 24
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS).
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS) Questionnaire.
NCT02374060 (15) [back to overview]	Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 24 Weeks
NCT02374060 (15) [back to overview]	Proportion of Baseline Central Subfield Thickness Observed at 24 Weeks
NCT02374060 (15) [back to overview]	Number of Eyes With Vitreous Hemorrhage
NCT02374060 (15) [back to overview]	Number of Eyes With Retinal Tear or Detachment
NCT02374060 (15) [back to overview]	Number of Eyes With Endophthalmitis
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation of >=10 mm Hg Over Baseline
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation >=30 mm Hg
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation >=24 mm Hg
NCT02374060 (15) [back to overview]	Change in Best-corrected Visual Acuity at 8 Weeks
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With Severe Vision Loss
NCT02374060 (15) [back to overview]	Change in Best-corrected Visual Acuity at 24 Weeks
NCT02374060 (15) [back to overview]	Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With Resolution of Macular Edema at 8 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With Resolution of Macular Edema at 24 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 8 Weeks
NCT02381652 (1) [back to overview]	Number of Treatment-Emergent Adverse Events: Cingal 13-02 vs. Cingal 13-01
NCT02420041 (10) [back to overview]	Change in Pain Score From Baseline to 2 Weeks Post-procedure Using the DoD/VA PRS
NCT02420041 (10) [back to overview]	Change in Pain Score From Baseline to 3 Months Post-procedure Using the DoD/VA PRS
NCT02420041 (10) [back to overview]	Change in Pain Score From Baseline to 30 Minutes Pre-procedure Using the Defense and Veterans Pain Rating Scale (DoD/VA PRS) 0-10
NCT02420041 (10) [back to overview]	Change in Pain Score Since SI Injection at 3 Months Post-procedure Using the DoD/VA PRS
NCT02420041 (10) [back to overview]	Satisfaction of Procedure as a Measure of Safety and Tolerability Using a Numerical Scale 1-5
NCT02420041 (10) [back to overview]	Satisfaction of Procedure as a Measure of Safety and Tolerability Using a Numerical Scale 1-5
NCT02420041 (10) [back to overview]	Impression of Change of Condition at 3 Months Post-procedure Using the PGIC Scale
NCT02420041 (10) [back to overview]	Impression of Change of Condition at 2 Weeks Post-procedure Using the Patient Global Impression of Change (PGIC) Scale
NCT02420041 (10) [back to overview]	Difference in Minutes Between a Sacroiliac Joint Injection Done With Ultrasound vs Fluoroscopy
NCT02420041 (10) [back to overview]	Change in Pain Score Since Sacroiliac (SI) Injection at 2 Weeks Post-procedure Using the DoD/VA PRS
NCT02519738 (1) [back to overview]	Decrease in Size (mm) of Granulation Tissue
NCT02576938 (8) [back to overview]	Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16
NCT02576938 (8) [back to overview]	Change From Baseline in the EASI at Week 16
NCT02576938 (8) [back to overview]	Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib
NCT02576938 (8) [back to overview]	Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)
NCT02576938 (8) [back to overview]	Percentage Change From Baseline in the EASI at Week 16
NCT02576938 (8) [back to overview]	Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16
NCT02576938 (8) [back to overview]	Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16
NCT02576938 (8) [back to overview]	Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16
NCT02577991 (5) [back to overview]	Neck Disability Index (NDI) Mean Percentage Score From Baseline Through 1 Year Post Op
NCT02577991 (5) [back to overview]	Median Visual Analog Scale Pain Score for Patients From Baseline Through 1 Year Post Op
NCT02577991 (5) [back to overview]	Percentage of Patients Reporting Mild/Moderate/Severe Dysphagia From Baseline Through 1 Year Post Op Measured With Bazaz Dysphagia Score
NCT02577991 (5) [back to overview]	Percentage of Patients Reporting Dysphagia/Severe Dysphagia Through EAT-10 From Baseline Through 1 Year Post-Op
NCT02577991 (5) [back to overview]	Percentage of Patients Reporting Abnormal Vocal Handicap Measured by the VHI-10 From Baseline Through 1 Year Post-Op
NCT02592629 (1) [back to overview]	Change in Pain Assessment
NCT02595398 (3) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02595398 (3) [back to overview]	Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks
NCT02595398 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02637323 (4) [back to overview]	Synovial Fluid Drug Concentrations (pg/mL) by Time Point Pooled Across FX006 Cohorts and TCA IR in Synovial Fluid
NCT02637323 (4) [back to overview]	Synovial Fluid Drug Concentrations (pg/mL) by Time Point Pooled Across FX006 Cohorts and TCA IR in Synovial Fluid
NCT02637323 (4) [back to overview]	Plasma Drug Concentrations (pg/mL) by Time Pooled Across FX006 Cohorts and TCA IR 40 mg Cohort
NCT02637323 (4) [back to overview]	Plasma Drug Concentrations (pg/mL) by Time Pooled Across FX006 Cohorts and TCA IR 40 mg Cohort
NCT02680301 (2) [back to overview]	Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis
NCT02680301 (2) [back to overview]	Number of Patients Adhering to Treatment Protocol
NCT02762370 (7) [back to overview]	Change in Average Blood Glucose From Baseline (Hour -48 to Hour -1) to Hour 1 to Hour 48 for FX006 32 mg Relative to TCA IR 40 mg.
NCT02762370 (7) [back to overview]	Glycemic Variability Coeffecient of Variation (CV)
NCT02762370 (7) [back to overview]	Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR
NCT02762370 (7) [back to overview]	Percent Time Blood Glucose Less Than 70 mg/dl, 70 - 180 mg/dl, 180.1 - 250.0 mg/dl, 250.1 - 350.0 mg/dl, and Greater Than 350.0 mg/dl
NCT02762370 (7) [back to overview]	Percent Time Blood Glucose Less Than 70 mg/dl, 70 - 180 mg/dl, 180.1 - 250.0 mg/dl, 250.1 - 350.0 mg/dl, and Greater Than 350.0 mg/dl
NCT02762370 (7) [back to overview]	Change From Baseline for Maximum Blood Glucose: Baseline Average Blood Glucose (Hour -72 to Hour -1) to Maximum Blood Glucose (Hour 1 to Hour 72) for FX006 32 mg Relative to TCA IR 40 mg
NCT02762370 (7) [back to overview]	Change From Baseline for Average Blood Glucose (mg/dL)
NCT02781818 (3) [back to overview]	Patient Rating of Impression of Treatment at Day 14
NCT02781818 (3) [back to overview]	Number of Days to Lesion Resolution in Combined Treatment Arms Compared to the Placebo Arm.
NCT02781818 (3) [back to overview]	Change in Pain From Baseline to Day 5
NCT02877485 (2) [back to overview]	Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.
NCT02877485 (2) [back to overview]	Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)
NCT02949024 (5) [back to overview]	CLS-TA Injections
NCT02949024 (5) [back to overview]	Mean Change From Baseline in Intraocular Pressure
NCT02949024 (5) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02949024 (5) [back to overview]	Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
NCT02949024 (5) [back to overview]	Best Corrected Visual Acuity
NCT02952001 (4) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02952001 (4) [back to overview]	Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
NCT02952001 (4) [back to overview]	Time to Additional Therapy for Uveitis
NCT02952001 (4) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT02980874 (3) [back to overview]	Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
NCT02980874 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02980874 (3) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT02996097 (2) [back to overview]	Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS)
NCT02996097 (2) [back to overview]	Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS)
NCT03002974 (25) [back to overview]	Change From Baseline in the Inflammatory Biomarker C Reactive Protein
NCT03002974 (25) [back to overview]	Change From Baseline in the Inflammatory Biomarker Serum Amyloid A
NCT03002974 (25) [back to overview]	Change in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale
NCT03002974 (25) [back to overview]	Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS
NCT03002974 (25) [back to overview]	Health Care Resource Utilization Due to a Gouty Arthritis Flare
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Erythema
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Swelling
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Tenderness
NCT03002974 (25) [back to overview]	Physician's Assessment of Global Response to Treatment
NCT03002974 (25) [back to overview]	Proportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra
NCT03002974 (25) [back to overview]	Proportion of Patients With Neutralizing Antibodies
NCT03002974 (25) [back to overview]	Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
NCT03002974 (25) [back to overview]	Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
NCT03002974 (25) [back to overview]	Change From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
NCT03002974 (25) [back to overview]	Patient´s Assessment of Global Response to Treatment (5-point Likert Scale)
NCT03002974 (25) [back to overview]	Median Time to First Intake of Rescue Medication From First Investigational Drug Administration
NCT03002974 (25) [back to overview]	Median Time to Onset of Effect
NCT03002974 (25) [back to overview]	Median Time to Resolution of Pain
NCT03002974 (25) [back to overview]	Median Time to Response
NCT03002974 (25) [back to overview]	The Percent of Patients With at Least One Adverse Event
NCT03002974 (25) [back to overview]	The Percent of Patients With at Least One Serious Adverse Event, Including Death
NCT03002974 (25) [back to overview]	Change From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score
NCT03011892 (10) [back to overview]	Time to Achieve EASI-50
NCT03011892 (10) [back to overview]	Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle
NCT03011892 (10) [back to overview]	Mean Percentage Change From Baseline in EASI Score at Week 2 and Week 8
NCT03011892 (10) [back to overview]	Percentage Change From Baseline in EASI Score at Week 4
NCT03011892 (10) [back to overview]	Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID
NCT03011892 (10) [back to overview]	Mean Change From Baseline in the Itch Numerical Rating Scale (NRS) Score at Weeks 2, 4, and 8
NCT03011892 (10) [back to overview]	Percentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Weeks 2, 4, and 8
NCT03011892 (10) [back to overview]	Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID
NCT03011892 (10) [back to overview]	Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 2, 4, and 8
NCT03011892 (10) [back to overview]	Number of Participants With At Least One Adverse Event (AEs) and as Per Severity
NCT03097315 (5) [back to overview]	Adverse Events
NCT03097315 (5) [back to overview]	Mean Intraocular Pressure in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Anterior Chamber Cells in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Vitreous Haze in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Anterior Chamber Flare in the Study Eye
NCT03115567 (3) [back to overview]	Change in Quality of Life Using FACT-EGFRI 18 Quality of Life Assessment
NCT03115567 (3) [back to overview]	Number of Participants in the Treatment and Control Group Who Adhere to Their Chemotherapy Regimen Determined by Whether Patients Discontinue Their Chemotherapy Regimen or Continue Their Full Course of Treatment
NCT03115567 (3) [back to overview]	% of Participants With Grade 2 Rash or Higher
NCT03126786 (2) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity Letter Score
NCT03126786 (2) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT03127137 (1) [back to overview]	Change in Strength in Both Groups After CESI.
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Physical Function Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	OMERACT-OARSI Responder Index at 26 Weeks Post Treatment Comparing the Cingal Group to the TH Group (ITT Population)
NCT03191903 (11) [back to overview]	The Usage of Rescue Medication (Acetaminophen) Through 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 3 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Stiffness Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in Patient Global Assessment at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in the Evaluator Global Assessment at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in Total WOMAC Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 1 Week (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 3 Weeks in the Per-Protocol Population
NCT03203447 (3) [back to overview]	Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
NCT03203447 (3) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT03203447 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT03378076 (2) [back to overview]	Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
NCT03378076 (2) [back to overview]	Incidence of Treatment Emergent Adverse Events
NCT03380026 (3) [back to overview]	Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring
NCT03380026 (3) [back to overview]	Efficacy of Valchlor vs Valchlor Plus Triamcinolone
NCT03380026 (3) [back to overview]	Severity of Dermatitis
NCT03382262 (2) [back to overview]	Total Number of Treatment Emergent Adverse Events
NCT03382262 (2) [back to overview]	Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
NCT03382821 (4) [back to overview]	Neck Disability Index-5
NCT03382821 (4) [back to overview]	"The Percentage of Participants Reporting Patient Global Impression of Change Score of 6-7 (Indicating Much Improved and Very Much Improved)"
NCT03382821 (4) [back to overview]	Percentage of Participants Reporting >6.8 Reduction on the Medication Quantification Scale III
NCT03382821 (4) [back to overview]	The Percentage of Participants With Reduction of 50% or More of Neck and Arm Pain NRS Score
NCT03390036 (8) [back to overview]	OMERACT-OARSI Responder Rate at 39 Weeks
NCT03390036 (8) [back to overview]	The Usage of Rescue Medication (Acetaminophen) at Week 39
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Pain Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in Total WOMAC Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in Patient Global Assessment at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Physical Function Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Stiffness Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in Evaluator Global Assessment at 39 Weeks
NCT03463915 (7) [back to overview]	Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire
NCT03463915 (7) [back to overview]	Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain
NCT03463915 (7) [back to overview]	Number of Participants With at Least One Adverse Event
NCT03463915 (7) [back to overview]	Pelvic Floor Distress Inventory (PFDI)
NCT03463915 (7) [back to overview]	Overactive Bladder Questionnaire (OAB-q)
NCT03463915 (7) [back to overview]	Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire
NCT03463915 (7) [back to overview]	Pelvic Pain and Urgency/Frequency (PUF) Questionnaire
NCT03586687 (4) [back to overview]	Change in Overall SPADI Scores for Those Receiving Shoulder Arthroplasty at 1 Year
NCT03586687 (4) [back to overview]	Change in Overall SPADI Scores at Baseline Compared to 2,4, and 6 Months.
NCT03586687 (4) [back to overview]	Assess Reactions to the Steroid
NCT03586687 (4) [back to overview]	Rate of Shoulder Arthroplasty Following Injection
NCT03636373 (4) [back to overview]	Joint Pain on Numeric Pain Scale
NCT03636373 (4) [back to overview]	Joint Pain Intensity in the Most Affected Joint
NCT03636373 (4) [back to overview]	Patient's Assessment of Response to Treatment
NCT03636373 (4) [back to overview]	Physician's Assessment of Response to Treatment
NCT03641508 (3) [back to overview]	Number of Participants With no Symptoms of Trigger Finger
NCT03641508 (3) [back to overview]	Number of Participants With no Symptoms of Trigger Finger
NCT03641508 (3) [back to overview]	Number of Participants With no Symptoms of Trigger Finger
NCT03758365 (2) [back to overview]	Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
NCT03758365 (2) [back to overview]	Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
NCT03797872 (1) [back to overview]	Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study
NCT03895840 (6) [back to overview]	30 Second Chair Standing Test
NCT03895840 (6) [back to overview]	40m Fast Paced Walking Test (40m FPWT)
NCT03895840 (6) [back to overview]	KOOS-PS (Knee Osteoarthritis Outcome Score - Physical Function Short Form)
NCT03895840 (6) [back to overview]	KOOS-QoL (Knee Osteoarthritis Outcome Score - Quality of Life)
NCT03895840 (6) [back to overview]	NRS for Pain
NCT03895840 (6) [back to overview]	Timed Stair Climb
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in Knee Pain as Measured by Visual Analog Scale (VAS) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	The Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index
NCT04231318 (15) [back to overview]	The Usage of Rescue Medication (Acetaminophen/Paracetamol) at 26 Weeks
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Stiffness Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in Knee Pain as Measured by Numerical Rating Scale (NRS) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Evaluator Global Assessment (EGA) Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Patient Global Assessment (PGA) Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT05438277 (1) [back to overview]	Incidence of a Flare Reaction

Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography

(NCT00105027)
Timeframe: 12 months

Intervention	um (Median)
CRVO Observation	-277
CRVO 1 mg Dose Triamcinolone Acetonide	-196
CRVO 4 mg Dose Triamcinolone Acetonide	-261
BRVO Standard Care	-224
BRVO 1 mg Dose Triamcinolone Acetonide	-149
BRVO 4 mg Dose Triamcinolone Acetonide	-170

Intervention	events (Number)
	Initiation of IOP-lowering medications	IOP > 35 mm HG	IOP > 10 mm HG above baseline	Laser peripheral iridotomy	Trabeculectomy	Tube shunt	Cataract: lens opacity onset or progression	Cataract surgery	Infectious endophthalmitis	Noninfectious endophthalmitis	Retinal detachment	Iris neovascularization	Retinal neovascularization	Vitreous hemorrhage	YAG capsulotomy	Sector or panretinal photocagulation	Pars plana vitrectomy
BRVO 1 mg Dose Triamcinolone Acetonide	11	2	12	0	0	0	27	0	0	0	1	1	1	1	0	1	0
BRVO 4 mg Dose Triamcinolone Acetonide	57	14	50	1	0	0	38	4	1	0	0	2	3	3	1	4	1
BRVO Standard Care	3	1	1	0	0	0	15	3	0	0	1	1	5	2	1	5	1
CRVO 1 mg Dose Triamcinolone Acetonide	18	5	15	0	0	2	20	0	0	0	0	9	2	4	0	9	2
CRVO 4 mg Dose Triamcinolone Acetonide	32	8	24	1	0	0	25	4	0	0	0	4	2	0	0	3	0
CRVO Observation	7	1	2	0	0	0	12	0	0	0	0	2	4	4	1	5	1

Intervention	letters read (Mean)
CRVO Observation	-12.1
CRVO 1 mg Dose Triamcinolone Acetonide	-1.2
CRVO 4 mg Dose Triamcinolone Acetonide	-1.2
BRVO Standard Care	4.2
BRVO 1 mg Dose Triamcinolone Acetonide	5.7
BRVO 4 mg Dose Triamcinolone Acetonide	4.0

Intervention	units on a scale (Mean)
Lidocaine 2% and Bupivacaine 0.25% Plus Saline	-3.29
Lidocaine 2% and Bupivacaine 0.25% Plus Triamcinolone 40 mg.	-3.70

Intervention	mm^2 (Mean)
	Baseline	12 Months	Change from Baseline
Verteporfin + 1 mg Triamcinolone	6.9178	6.8959	-0.0219
Verteporfin + 4 mg Triamcinolone	5.6400	5.8149	0.1749
Verteporfin + Pegaptanib	6.3011	8.6245	2.3234

Intervention	Participants (Number)
	Participants who received 1 treatment	Participants who received 2 treatments	Participants who received 3 treatments	Participants who received 4 treatments
Verteporfin + 1 mg Triamcinolone	11	10	9	2
Verteporfin + 4 mg Triamcinolone	12	15	12	2
Verteporfin + Pegaptanib	10	19	5	4

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	31.3
Verteporfin + 4 mg Triamcinolone	12.2
Verteporfin + Pegaptanib	28.9

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	59.4
Verteporfin + 4 mg Triamcinolone	63.4
Verteporfin + Pegaptanib	71.1

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	18.8
Verteporfin + 4 mg Triamcinolone	2.4
Verteporfin + Pegaptanib	23.7

Intervention	participants (Number)
	Frequency - Missing	Frequency - Better	Frequency - Same	Frequency - Worse	Severity - Missing	Severity - Better	Severity - Same	Severity - Worse
Placebo	1	8	18	13	2	6	19	13
Triamcinolone Acetonide	0	11	14	13	0	9	17	12

Intervention	ears (Number)
	Initial Tympanogram of Type B or C	6 weeks Complete Normalization (Type A)
Placebo	57	20
Triamcinolone Acetonide	55	12

Intervention	Microns (Median)
Focal/Grid Laser Photocoagulation	243
1mg Intravitreal Triamcinolone	305
4 mg Intravitreal Triamcinolone	279

Intervention	Microns (Mean)	Microns (Median)
Focal/Grid Laser Photocoagulation	-175
1mg Intravitreal Triamcinolone	-124
4 mg Intravitreal Triamcinolone	-126
Focal/Grid Laser Photocoagulation	-158
1mg Intravitreal Triamcinolone	-103
4 mg Intravitreal Triamcinolone	-114

Intervention	Microns (Mean)
Focal/Grid Laser Photocoagulation	-139
1mg Intravitreal Triamcinolone	-86
4 mg Intravitreal Triamcinolone	-77

Intervention	Microns (Median)
Focal/Grid Laser Photocoagulation	-131
1mg Intravitreal Triamcinolone	-74
4 mg Intravitreal Triamcinolone	-76

Intervention	Percentage of Eyes (Number)
	>= 15 letter improvement	14 to 10 letter improvement	9 to 5 letter improvement	same +- 4 letters	5-9 letters worse	10-14 letters worse	>=15 letters worse
1mg Intravitreal Triamcinolone	14	11	14	27	9	6	20
4 mg Intravitreal Triamcinolone	17	11	15	23	6	8	20
Focal/Grid Laser Photocoagulation	18	13	16	24	10	5	14

Intervention	Percentage of Eyes (Number)
	>= 15 letters better	10-14 letters better	5-9 letters better	no change, + - 4 letters	5-9 letters worse	10-14 letters worse	>=15 letters worse
1mg Intravitreal Triamcinolone	20	4	17	23	10	9	17
4 mg Intravitreal Triamcinolone	21	16	9	24	6	6	16
Focal/Grid Laser Photocoagulation	26	18	18	21	4	4	8

Intervention	letter score (Mean)
	4 Weeks	8 Weeks	17 Weeks	34 Weeks
Anterior Peribulbar Injection of 20 mg Triamcinolone	80	80	79	80
Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser	77	77	77	77
Focal Laser Photocoagulation	79	79	78	78
Posterior Peribulbar Injection of 40 mg Triamcinolone	79	79	78	76
Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser	77	80	79	77

Intervention	eyes (Number)
	Eyes that were retreated	Eyes with ≥ 250 central subfield thickness
Anterior Peribulbar Injection of 20 mg Triamcinolone	14	16
Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser	9	13
Focal Laser Photocoagulation	22	26
Posterior Peribulbar Injection of 40 mg Triamcinolone	15	14
Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser	9	11

Intervention	Units on a scale (Mean)
	Pain VAS at Baseline	Pain VAS at 26 weeks
Bupivicaine	57.1	42.9
Hylan G-F 20	60.7	49.8
Triamcinolone	63.2	50.1

Intervention	units on a scale (Mean)
	DASH at Baseline	Dash at 26 Weeks
Bupivicaine	25.7	24.2
Hylan G-F 20	28.8	26.1
Triamcinolone	28.9	27.0

triamcinolone

Description

Cross-References

Synonyms (177)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (11)

Protein Targets (59)

Potency Measurements

Inhibition Measurements

Biological Processes (97)

Molecular Functions (48)

Ceullar Components (24)

Bioassays (172)

Research

Studies (3,718)

Market Indicators

Research Demand Index: 125.62

Study Types

Clinical Trials (480)

Trial Overview

Trial Outcomes

Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography

The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit

Adverse Ocular Outcomes

Changes From Baseline in Best-corrected ETDRS Visual Acuity Score

Headache Severity as Measured on an 11-point Verbal Scale (0 to 10):0=No Pain 10=Excruciating Pain

Mean Change From Baseline in Total Area of Lesion at 12 Months

Number of Participants Requiring Verteporfin Treatment Throughout the Study

Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12

Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.

Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months

Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12

Number of Subjects With Change in Symptom Frequency and Severity - Popping Sensation in Ears

Per-Ear Treatment Outcome

Number of Subjects With Change in Symptom Frequency and Severity - Plugged Sensation in Ears

Number of Subjects With Change in Symptom Frequency and Severity - Fullness or Pressure in Ears

Number of Subjects With Change in Symptom Frequency and Severity - Dampened Hearing/Loss Worse Than Usual

Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment

Complete Normalization of Abnormal Tympanometry Considering the Subjects Who Took Additional Treatment as Having Incomplete Resolution

Number of Subjects With Change in Symptom Frequency and Severity - Pain in Ears

Central Subfield Thickness at 2 Years

Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years

Change in Central Subfield Thickness on OCT Baseline to 3 Years

Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.

Change in Visual Acuity From Baseline to 3 Years

Change in Visual Acuity From Baseline to 3 Years

Mean Change in Central Subfield Thickness Baseline to 2 Years

Median Change in Central Subfield Thickness Baseline to 2 Years

Median Change in Visual Acuity Baseline to 2 Years

Overall Central Subfield Thickening Decreased by >=50% Baseline to 2 Years

Percentage of Eyes With a Change in Central Subfield Thickness on OCT <250 Microns From Baseline to 3 Years

Distribution of Change in Visual Acuity Baseline to 2 Years

Distribution of Visual Acuity Change Baseline to 3 Years

Central Subfield Thickness < 250 Microns at 2 Years

Mean Visual Acuity Letter Score at Each Follow-up Visit

Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks

Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks

Change in Visual Acuity Letter Score From Baseline Through 34 Weeks

Change in Central Subfield Thickening From Baseline Through 34 Weeks

Central Subfield Thickness <250 Microns From Baseline Through 34 Weeks

Pain Visual Analogue Scale (VAS)

Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire

Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year

Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness

Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator

Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity

Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score

Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline

Number of Injections in First Year

Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema

Intervention	Eyes (Number)
	≥15 letter improvement	14-10 letter improvement	9-5 letter improvement	Same ±4 letters	5-9 letters worse	10-14 letters worse	≥15 letters worse
0.5 mg Ranibizumab+Deferred Laser	52	36	54	35	5	2	4
0.5 mg Ranibizumab+Prompt Laser	57	38	34	38	14	3	3
4 mg Triamcinolone+Prompt Laser	39	22	32	54	12	12	15
Sham+Prompt Laser	43	38	67	86	20	16	23

Intervention	Letters (Mean)
	<400 microns	≥400 microns
0.5 mg Ranibizumab+Deferred Laser	7	11
0.5 mg Ranibizumab+Prompt Laser	7	11
4 mg Triamcinolone+Prompt Laser	3	6
Sham+Prompt Laser	3	3

Intervention	Letters (Mean)
	Typical/predominantly focal	Neither predominantly focal nor diffuse	Typical/predominantly diffuse
0.5 mg Ranibizumab+Deferred Laser	8	8	10
0.5 mg Ranibizumab+Prompt Laser	8	10	9
4 mg Triamcinolone+Prompt Laser	3	3	5
Sham+Prompt Laser	3	2	3

Intervention	Letters (Mean)
	Moderately severe non-proliferative DR or better	Severe non-proliferative DR or worse
0.5 mg Ranibizumab+Deferred Laser	9	9
0.5 mg Ranibizumab+Prompt Laser	10	8
4 mg Triamcinolone+Prompt Laser	3	5
Sham+Prompt Laser	3	2

Intervention	Letters (Mean)
	≥66 (better than 20/50)	≤65 (20/50 or worse)
0.5 mg Ranibizumab+Deferred Laser	5	13
0.5 mg Ranibizumab+Prompt Laser	6	12
4 mg Triamcinolone+Prompt Laser	1	7
Sham+Prompt Laser	1	5

Intervention	Letters (Mean)
	Not pseudophakic at baseline	Pseudophakic at baseline
0.5 mg Ranibizumab+Deferred Laser	10	7
0.5 mg Ranibizumab+Prompt Laser	9	8
4 mg Triamcinolone+Prompt Laser	2	8
Sham+Prompt Laser	2	4

Intervention	Eyes (Number)
	Improved by 2 or more levels	Worsened by 2 or more levels
Ranibizumab	18	1
Sham	10	7
Triamcinolone	6	2

Intervention	Participants (Number)
	Nonfatal myocardial infarction	Nonfatal cerebrovascular accident	Vascular death	Any ATC cardiovascular event
Ranibizumab	1	3	7	11
Sham	3	5	4	10
Triamcinolone	2	1	2	5

Intervention	mm^3 (Mean)
Sham+Prompt Laser	-1.0
0.5 mg Ranibizumab+Prompt Laser	-1.4
0.5 mg Ranibizumab+Deferred Laser	-1.5
4 mg Triamcinolone+Prompt Laser	-1.4

Intervention	microns (Mean)
Sham+Prompt Laser	-102
0.5 mg Ranibizumab+Prompt Laser	-131
0.5 mg Ranibizumab+Deferred Laser	-137
4 mg Triamcinolone+Prompt Laser	-127